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ABSTRACT
Background Within this thesis we have examined the effects on vascular tone of two
peptide hormones, urotensin II and vasopressin. Human urotensin II is a novel
vasoactive peptide hormone with receptors located on human arterial tissue and
ventricular myocytes. It is the most potent arterial vasoconstrictor yet discovered and
has a sustained effect on blood vessels from a variety of species with potency 28 to 50
fold greater than endothelin-1. Vasopressin has however, been known to have arterial
vasoconstrictor properties inman in vivo formany years. However, peptide antagonists
for the VI receptor, mediating vasoconstriction, and the V2 receptor, mediating
vasodilatation, have often been ofpoor selectivity and subject to inter-species variation,
thus clouding the true arterial pharmacodynamic effects of vasopressin. Two novel
peptidic arginine vasopressin antagonists have recently been produced and offer
potentially more receptor selectivity.
Objectives The aims of this thesis were: first to assess the effects of urotensin II on
human resistance vessels and venous tone in vivo; second, to study the effects of
systemic intravenous urotensin II on human haemodynamics such as blood pressure,
pulse, vascular resistance and arterial stiffness; third, to explore the human in vivo
pharmacodynamics of vasopressin in human resistance vessels in the skin
microcirculation and forearm as preparation for VI and V2 receptor antagonist studies;
forth, to demonstrate that vasopressin induced vasodilatation is mediated by nitric oxide;
and finally, fifth, to combine novel VI and V2 receptor antagonists with vasopressin in
the human skin and forearm to assess the efficacy of novel vasopressin peptide
antagonists.
Methods Using the established method ofbilateral venous occlusion plethysmography
to measure forearm blood flow, combined with intra-arterial infusion of drugs into the
brachial artery, we sought to determine the effects ofurotensin II on human forearm
blood flow. Other methods such as the Aellig venous displacement technique, to assess
venous tone, and pulse wave analysis, to quantify arterial stiffness were also used during
local and systemic urotensin II intravenous infusions respectively. Doppler flowmetry
was used to assess skin microcirculation combined with intra-dermal peptide injection
we assessed skin blood flow in response to vasopressin alone and in combination with a
novel selective VI antagonist. Venous occlusion plethysmography was again used to
determine forearm blood flow responses to vasopressin alone and in combination with
VI and V2 antagonists.
Results During intra-arterial infusion ofurotensin II we did not observe any significant
changes in forearm blood flow, even in the presence of endothelial inhibitors such as
aspirin and a 'nitric oxide clamp' nor was change observed in venous tone. Moreover,
no alteration in systemic haemodynamics or arterial stiffness was seen during systemic
intravenous infusion. We observed a significant fall in skin blood flow with intra¬
dermal injection of vasopressin, however, the VI receptor antagonist did not alter skin
vasoconstriction. Intra-arterial infusion of vasopressin caused a reproducible biphasic
change in forearm blood flow, low doses causing vasoconstriction and high doses, nitric
x
oxide mediated vasodilatation. Vasodilatation was subject to tachyphylaxis during
prolonged infusion ofhigh dose vasopressin. Neither intra-arterial VI or V2 antagonist,
when co-infused with vasopressin, altered this biphasic vasoconstriction and
vasodilatation.
Conclusion The majority of our findings for urotensin II were in contrast to our
hypothesis. Until a selective urotensin II antagonist is developed the physiological role
of urotensin II in human cardiovascular physiology will remain difficult to ascertain. Its
role may alternatively lie in longer term regulation of vascular tone or in sodium and
metabolic homeostasis. We defined the pharmacodynamics of vasopressin in humans in
vivo to a greater depth than previous studies and confirmed, using a 'nitric oxide clamp',
the dependence of vasopressin induced vasodilatation on locally derived nitric oxide.
Both vasopressin antagonists have yet again been subject to considerable inter-species
variation, as demonstrated by the efficacy of the VI receptor antagonist in our rat
biopressor assay. To date there are no truly selective peptidic vasopressin receptor
antagonists available for human in vivo studies.
xi
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1.1.1 Origins of Urotensin II
The "urotensins" are a group ofpeptides that were discovered within the tissue extracts
of the urophysis, a caudal neurosecretory organ of the teleost fish. They were loosely
classified into urotensin I to V, urotensin I and II being transcribed from different genes.
Urotensin I is a longer peptide with 41 amino acids and is similar to corticotrophin
releasing factor in man. Urotensin II was first characterised in 1967 from teleost fish
[Bern et al 1967] and sequenced in 1980 [Pearson et al 1980]. It is a dodecapeptide, the
cyclical moiety being the biologically active site. The concept that urotensin II was
restricted to marine species was challenged only later when it was isolated from frogs
[Conlon et al 1992], mice, rats and humans [Coulouarn et al 1998, Coulouarn et al
1999], Although the number of amino acids that formed urotensin II differs amongst
species, it is of potentially great evolutionary significance given that the biologically
active cyclical portion of the peptide is entirely unchanged (Figure 1.1.1). This is
despite the obvious ancestral divergence ofman and the river lamprey (Lampetra
Fluviatilis), the oldest know species to have urotensin II, occurring 550 million years
ago [Waugh et al 1995], In the context of the future finding that urotensin II caused
profound vasomotor changes in mammalian studies, the potential reasons for careful
evolutionary preservation of this peptide is of great interest.
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Figure1.1.1 ThestructureofurotensinIIandva iationm ng tspeci[Coul uareal1998]. CarpUrotensinIIFrogUrotensinII
PorcineUrotensinII
HumanUrotensiII
1.1.2 Characteristics of human urotensin II
Human urotensin II (hUII) is an 11 amino acid peptide (Figure 1.1.1). It is cleaved from
a larger 130 amino acid prepro urotensin II precursor that itself is transcribed from a 688
base pair strand ofDNA [Ames et al 1999], Human prepro urotensin II mRNA was first
located in the spinal cord, particularly in the motor neurones. Lesser concentrations
have been found in other human tissues including kidney, spleen, small intestine,
thymus, prostate, pituitary and adrenal glands, stomach, pancreas, liver and ovary
[Coulouarn et al 1998]. Of all the organs, including the central nervous system, the
kidney has the highest mRNA expression of prepro urotensin II [Nothacker et al 1999].
1.1.3 Discovery and characteristics of the urotensin II receptor
The receptor and ligand, were brought together by means of "reverse pharmacology".
Using sequence homology, genomic DNA library screening and the polymerase chain
reaction a rat "orphan receptor", called GPR-14, was identified [Marchese et al 1995]
("orphan receptor" refers to a receptor with an as yet undiscovered physiological and/or
pharmacological ligand). It was shown to have features consistent with those ofG-
protein coupled receptors with 7 hydrophobic transmembrane domains and a third
intracellular loop, indicative of a peptide binding receptor. Reverse pharmacology
involves the expression of the orphan receptor on cultures cells allowing the trial of
various potential ligands, a potentially protracted process [Stadel et al 1997]. Clues
from the GPR-14 receptor such as its similarity to somatostatin receptors did suggest the
ligand to be peptidic. By assessing the second messenger responses, including changes
in intracellular Ca2+, stimulatory ligands could be identified and in 1999 Lui et al
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showed that frog urotensin II was an agonist ligand [Lui et al 1999]. Using similar
techniques to Marchese et al, the human genome was probed for the GPR-14 equivalent
gene and was located on chromosome 17 and the receptor had high affinity binding for
both fish and human urotensin II [Ames et al 1999; Nothacker et al 1999]. Using
immunohistochemistry on human tissues, the receptor distribution has been mapped to
show extensive binding to cardiovascular tissues including coronary arteries, internal
mammary arteries and ventricular cardiac myocytes [Ames et al 1999; Maguire et al
2000], It seems likely that the kidney, with its high prepro urotensin II expression, is the
source of circulating urotensin II and that urotensin II acts as an endocrine hormone.
1.1.4 In vitro animal evidence for urotensin II as a vasoactive peptide
The mammalian vasomotor effects ofurotensin II first came to light when rat arterial
strips from the most proximal and distal circulatory sites where exposed, in vitro, to fish
urotensin II with subsequent vascular smooth muscle contraction. Moreover, the
thoracic aorta was the most sensitive with progressive loss of effect through abdominal
aorta, mesenteric and femoral arteries [Itoh et al 1987; Gibson 1987]. The pattern of
effects corresponded to the distribution of receptors as shown by radio-labelled fish
urotensin II [Itoh et al 1988]. To investigate the specificity of the urotensin II response
investigators used agents that block a and |3 adrenergic receptors, cholinergic,
histaminergic and serotonergic receptors and all failed to change the urotensin response
[Gibson 1987; Itoh et al 1987]. The second messenger system was also scrutinised and
it appears that the activity ofphospolipase C [Gibson 1987], inositol phosphates
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[Opgaard et al 2000] and Ca2+ [Gibson et al 1988] are essential for the vasoactive
response. Human urotensin II has been used in similar in vitro studies on non-human
primate vessels where it exceeded the potency of endothelin-1 and caused
vasoconstriction in all arteries tested, although these were all conduit arteries [Ames et
al 1999]. In addition, there was clearly a preferential effect on arterial over venous
tissue, a selective feature not seen with endothelin-1 responses [Ames et al 1999].
However, despite the above evidence, some animal studies have demonstrated variation
in response between species [Douglas et al 2000] as well as the anatomical variation in
response and moreover, vasodilator [Katano et al 2000; Stirrat et al 2001] responses and
potential interaction with nitric oxide have been uncovered [Bottril et al 2000; MacLean
et al 2000]. Furthermore, the activity of human urotensin II extends beyond the vascular
tree causing contraction of primate airway [Hay et al 2000], although receptormapping
has not yet been performed for these tissues.
1.1.5 In vivo animal responses to urotensin II
Animal in vitro studies have given mixed results and must be considered in light of the
in vivo investigations. At low intravenous doses ofhuman urotensin II in Cynomologous
monkey cardiac output increased slightly without a change in mean arterial pressure. In
contrast higher dose ranges caused a dose dependent increase in vascular resistance,
bradycardia and decrease in cardiac output with haemodynamic and echocardiography
evidence of severe depression ofmyocardial contractility (Figure 1.1.2) [Ames et al
1999]. Despite these significant changes mean arterial pressure did not change. In some
6
cases the dose was sufficient to cause total cardiovascular collapse and death.
Electrocardiographic (ECG) recordings during the studies did show marked ST segment
depression (Figure 1.1.3) coinciding with reduced stroke volume and contractility as
determined by echocardiography. Equivalent doses of endothelin-1 had no such effects
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ECG changes in anaesthetised cynomologous monkey during human urotensin II
[Personal communication from S.A. Douglas].
Baseline Lead 11 ECG
2 minutes post h Urotcnsiii II
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4 minutes post h Uratcnsin U
UAiAJAiAJA.
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1.1.6 Potential role of urotensin in human cardiovascular regulation and
pathophysiology
The systemic haemodynamic findings in the non-human primates were intriguing, as is
the degree to which this peptide has been preserved through so many species over
millions of years of evolution. Exactly what role urotensin II plays in the either
homeostasis or in pathophysiology ofman and animals is not yet clear. Some
investigators have now shown that urotensin II plasma concentrations are increased in
end stage cirrhosis [Heller J et al 2002] and heart failure [Richards et al 2002],
Furthermore, in patients with heart failure, the myocardial expression of urotensin II and
its human receptor are both increased. This has led to speculation that urotensin II may
be involved in the pathophysiological circulatory states found in both these diseases.
Whether urotensin II influences vascular tone alone or also plasma volume is not yet
clear but given that the kidney is the most likely source of circulating urotensin in man
[Nothacker et al 1999], urotensin II may have a possible role in water and electrolyte
homeostasis.
At the level of the endothelium, urotensin II receptors have been located in human
coronary atheromatous plaque using immunostaining; particularly in lipid laden smooth
muscle/macrophage rich areas of plaques [Ames et al 1999], Watanabe has also
demonstrated that urotensin II augments the proliferative effects of partly oxidised LDL-
cholesterol on vascular smooth muscle cells [Watanabe et al 2001].
10
Few data have emerged on the basic physiological responses ofurotensin II in man in
vivo and how theymight compare to a well established endocrine hormone. Nor
unfortunately is there an antagonist to help clarify the true role ofhuman urotensin II in
vitro and in vivo.
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1.2 VASOPRESSIN
1.2.1 Origins of vasopressin
Arginine vasopressin (AVP), also known as anti-diuretic hormone, was first studied
indirectly by Oliver and Shafer in 1895 when they discovered that pituitary gland
extracts had potent pressor actions [Oliver and Shafer 1895], Both vasopressin and
oxytocin are secreted from the posterior pituitary gland where axons from the supraoptic
and paraventricular nuclei of the hypothalamus terminate. Vasopressin is formed
predominantly in the supraoptic nucleus and oxytocin in the paraventricular nucleus.
Despite differing in only two amino acids (positions 3 and 8) vasopressin and oxytocin
serve very different endocrine functions (see Figure 1.2.1 for structure of vasopressin).
The main endocrine functions of vasopressin are to control body water and osmolality
and the contraction of vascular smooth muscle, whereas oxytocin is responsible for
uterine contraction and milk letdown reflexes. While the cardiovascular and renal
effects of vasopressin are well described, the central nervous system actions of
vasopressin still raise many questions [Barberis and Tribollet 1996] where it acts as a
neurotransmitter/neuromodulator ofmajor body functions including blood pressure,
body temperature, memory, anterior pituitary hormone secretion and brain development.
12
Figure 1.2.1
The structure of vasopressin (note the disulphide bond between cysteine residues













1.2.2 Characteristics of vasopressin
Vasopressin is a cyclical nonapeptide and like many hormonal peptides is cleaved from
a larger molecule, prepropressophysin, which is produced in the cell bodies of the
supraoptic neurones and then transported by carrier proteins, called neurophysins, to the
posterior pituitary. During transit the translated prepropressophysin molecule is split
and stored in histologically evident "Herring" granules of free vasopressin, neurophysin
II and glycopeptide ready for release into adjacent capillaries. Beyond the stage of
release, it is unknown if neurophysin II has a further role. Normal circulating
concentrations of vasopressin is in the approximate range of 0.9 to 6.5 pmol/L increasing
to as high as 187 pmol/L during extreme stimuli [Landry and Oliver 2001]. Stimuli that
provoke the release of vasopressin are wide and numerous as listed in the table below.
Table 1.2.1























Atrial naturetic peptide (ANP)
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1.2.3 Vasopressin receptors and their functions
Receptors for vasopressin are distributed widely within the central nervous system and
the rest of the body. There are 3 subtypes, the VI, V2 and V3 receptor forms and all are
G protein coupled receptors (see Figure 1.2.2 for structure ofVI and V2 receptors). The
majority of the central nervous system receptors are VI but receptor subtypes exist in
different quantities throughout the rest of the body. The principal effect of vasopressin
on the periphery is to contract arterial vascular smooth muscle cells, via VI receptors
and to enhance water reabsorption in the medulla of the kidney via V2 receptors. The
V3 receptor primarily mediates the release of adrenocorticotrophin from the anterior
pituitary [Lui 1994], thus influencing steroidogenesis from the adrenal cortex. VI
receptors also exist on hepatocytes (causing glycogenolysis and gluconeogenesis),
platelets, renal medullary collecting duct cells, spleen and the zona glomerulosa and
zona fasiculata of the adrenal gland [Thiobonnier et al 2001]. On binding the VI
receptor, vasopressin activates phospholipase C allowing formation of inositol 1,4,5
triphosphate and diacylglycerol thus activating numerous protein kinases (Figure 1.2.3)
[Thiobonnier 1992; Birley et al 1994; Granot et al 1993; Thiobonnier et al 2000]. In
addition to vascular contraction, AVP mediates mitogenic stimuli, again via the VI
receptor, increasing cell protein synthesis and content with resultant hypertrophy and
proliferation [Thiobonnier et al 2000]. The V2 receptor is principally located on the
basolateral membrane of the collecting duct cells in the renal medulla, although it
probably exists in the vasculature as well. In the kidney it enhances water reabsorption
via increased transcription of aquaporin 2 protein, increases urea permeability into the
collecting ducts, and stimulates sodium reabsorption at the cortical and outer medullary
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collecting ducts [Bankir 2001]. In contrast to the VI receptor, vasopressin binding to
V2 receptors causes stimulation of adenylate cyclase increasing intracellular cAMP
(Figure 1.2.4). Both receptors are internalised within the cell after vasopressin binding
leading to receptor desensitisation [Lutz et al 1993; Fishman et al 1985]. Up to 90% of
receptors are internalised after vasopressin binding, the half life of such a process being
5 and 13 minutes for the VI and V2 receptors respectively [Thiobonnier et al 1992].
Receptors are recycled after vasopressin removal and return to the cell membrane in 20
minutes.
In its endocrine capacity, vasopressin is released under osmotic control to regulate
permeability of the renal collecting ducts to water. Vasopressin is also under baroreflex
control causing vasoconstriction in response to hypotension. The former mechanism is
by far the more sensitive mode of control, with collecting duct permeability regulation
occurring between 1 and 6 pmol/L (i.e. within the normal circulating vasopressin range),
its vasoconstrictor effects are however, mediated at higher concentrations, up to 187
pmol/L. As part of the early response to hypotension, vasopressin plasma concentration
is increased by up to 50-fold. The rapid rise in vasopressin helps maintain arterial
pressure but, as has been shown in animal hypotension models, is not sustained and falls
over several hours to a modestly elevated level [Morales et al 1999]. This most likely
reflects vasopressin depletion from the neurohypophysis [Negro-Vilar et al 1979].
16
Figure 1.2.2
The structure ofboth vasopressin receptors [Thibonnier et al 2001].
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Figure 1.2.3
Detailed intracellular pathways coupled to the activation of the human VI receptor









Abbreviations: a, alpha subunits; (3y, beta-gamma dimers of G-proteins; PLC,
phospholipase C; PLD, phospholipase D; PLA2, phospholipase A2; IP3, inositol-1,4,5
triphosphate; DAG, diacylglycerol; PKC, protein kinase C; AA, arachidonic acid; CO,
cyclo-oxygenase; EPO, epoxygenase; PA, phosphatidic acid; ERK, extracellular signal-
regulated kinase; MEK, mitogen activated ERK kinase; MAPK, mitogen activated
protein kinase; SEK, SAPK/ERK kinase; cAMP, cyclic AMP; PKA, protein kinase A;
APQ2, aquaporin 2 protein.
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Figure 1.2.4
Detailed intracellular pathways coupled to the activation of the human V2 receptor









Abbreviations: as for Figure 1.2.3
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1.2.4 Localised human vascular studies
The direct vascular actions of parenteral vasopressin administration have been explored
in clinical studies for many years [Kitchin 1957], However, despite this, the direct
vascular actions of vasopressin are controversial and the evidence conflicting. Some
workers have found that intra-arterial vasopressin causes vasoconstriction only [Weber
et al 1997] whilst others report isolated vasodilatation [Hirsch et al 1989]. This
disparity is likely to reflect a biphasic vascular response with vasopressin infusion
causing an initial vasoconstriction at low doses (1-10 pmol/min) followed by
vasodilatation at higher doses (>10 pmol/min) [Kitchin 1957; Hirsch et al 1989; Tagawa
et al 1993; Suzuki et al 1989]. This is consistent with a predominantly VI receptor
mediated effect with low concentrations and possibly "vascular V2 like" receptor effects
at higher concentrations, and is borne out by the potentiation of vasopressin induced
vasodilatation when administered in the presence ofVI receptor antagonism [Imaizumi
et al 1992; Hirsch et al 1989]. Although the physical presence of extra-renal V2
receptors in arteries has yet to be demonstrated, there is strong pharmacological
evidence for their existence. Intra-arterial infusion of desmopressin, a synthetic V2
receptor agonist, causes vasodilatation in the human forearm which can be abolished by
selective V2 antagonism [Tagawa et al 1995]. In addition, patients with congenital
diabetes insipidus due to a genetic defect in the V2 receptor do not respond to intra¬
arterial desmopressin and demonstrated only vasoconstriction in the face of increasing
doses of vasopressin [Van Lieburg et al 1995],
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1.2.5 Vasopressin induced arterial vasodilatation
The mechanism of vasopressin and desmopressin mediated vasodilatation has been
poorly characterised. Previous studies have suggested that it is independent of
prostaglandin production but is, in part, mediated by nitric oxide [Tagawa et al 1993;
Okamura et al 1999]. However, the demonstration of the contribution of nitric oxide
C'
was achieved by the co-infusion of L-N -monomethyl arginine which causes basal
vasoconstriction and makes interpretation of the subsequent blood flow responses
unclear. Moreover, other groups have reported desmopressin induced vasodilatation is
reduced by indomethacin but not by nitric oxide synthase inhibition [Aldasoro et al
1997; Medina et al 1999].
1.2.6 Endothelial, haemostatic and fibrinolytic effects of vasopressin receptor
agonists
Vasopressin causes platelet aggregation through VI receptor stimulation [Thibonnier et
al 1999], and may release haemostatic (von Willebrand factor, vWf, and Factor VIII:C),
fibrinolytic (tissue plasminogen activator, t-PA) and cytokine (interleukin-6, IL-6, and
tumor necrosis factor, TNF) factors through V2 receptor stimulation using intra-arterial
desmopressin [Newby et al 2000; Kaufmann et al 2000].
1.2.7 Differential responses to infused vasopressin in man
Distinct from its effects on total forearm blood flow, vasopressin also causes a dose-
dependent reduction in skin blood flow when given intra-dermally [Hirsch et al, 1989;
Weber et al, 1997] suggesting the presence of vascular bed specific differential VI and
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vascular V2 like receptor expression. Indeed intra-brachial vasopressin at high dose
increases the composite measure of total forearm blood flow whilst both skin and radial
artery blood flow decrease [Hayoz et al. 1997]. Despite the name, and given that in
vitro [Ohlstein et al. 1986] and in vivo it causes vasoconstriction, when given
systemically to healthy volunteers vasopressin causes only modest changes in heart rate
but little change in mean arterial blood pressure [Aylward et al. 1986],
1.2.8 Potential role of vasopressin in disease states
Heart failure is characterised by increased vascular tone, water retention and subsequent
oedema and dilutional hyponatraemia [Burrell et al 2000]. It has been suggested that a
pathologically activated vasopressin axis may lead to many of the features we associate
with heart failure although the exact role of vasopressin in heart failure remains
controversial. It appears likely that during heart failure, hypo-perfusion leads to
activation of the sympathetic nervous system, which in turn increases vasopressin
release. This is supported by increased plasma vasopressin concentrations in patients
with heart failure [Goldsmith et al 1983; Preibisz et al 1983; Schrier et al 1998]. This is
particularly so in the case of patients with heart failure and hyponatraemia [Szatalowicz
et al 1981], a feature of heart failure that confers a poor prognosis. Moreover, for
unknown reasons, plasma vasopressin concentrations remain elevated despite adequate
water loading in patients with heart failure [Goldsmith et al. 1986], it may be that non-
osmotic stimuli are able to over-ride the osmotic control mechanisms. Although the
rises in plasma vasopressin are modest in patients with heart failure, the levels in
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subjects with haemodynamic instability and/or hyponatremia are often 10 to 20-fold
higher [Nicod et al, 1984].
Stimulation of the V2 receptor with desmopressin has been implicated in the endothelial
release of haemostatic and fibrinolytic factors such as vWf factor VIII:C, t-PA and
endothelial derived cytokines [Cash et al 1974; Mannucci et al 1975; Newby et al 2000].
The balance of such cytokines and haemostatic factors is altered by vascular injury
[Sporn et al 1986] and inflammatory states, including atherosclerosis and a higher risk
of coronary events is conferred by their imbalance [Nusinow et al 1986; Blann et al
1994; Haverkate et al 1995; Thompson et al 1995].
1.2.9 Peptidic vasopressin antagonists
Recently, many selective and non-selective oral non-peptidic vasopressin antagonists
have been developed [Imaizumi et al 1992; Weber et al 1997]. However, for over 15
years, peptidic antagonists have been available for parenteral use and preliminary
clinical studies in heart failure were conducted using the VI receptor antagonist,
d(CH2)5Tyr(Me)AVP [Nicod et al 1985]. This antagonist does, however, have partial
V2 agonist effects and cannot be viewed as a purely selective antagonist. In contrast,
d(CH2)5[Tyr(Me)2,Dab5]AVP and d(CH2)5[D-Ile2,Ile4,Tyr-(NH2)9]AVP are more
selective VI and V2 receptor antagonists (Figure 1.2.5) [Chan et al 1996; Cotte et al
1998], The effect of intra-arterial administration of these more selective peptidic
antagonists has not been previously described in man.
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Figure1.2.5 Structuresofselectivep ptidicvaso ressinantagonist VIantagonist[Chetl2000] CH2-CO-Tyr(Me)-Phe-Gln-Dab-Cys-Pro-Arg-Gly-NH2 >C V2antagonist[Cotteetl1998] CH2-CO-D-Ile-Phe-Ile-Asn-Cys-Pro-Arg-Ala-NH2 >C
1.3 HYPOTHESIS
The relative preservation of the amino acid sequence in urotensin II across many species
suggests that it plays a highly significant role in animal physiology. The in vivo studies
using human urotensin II in non-human primates demonstrated substantial
haemodynamic changes [Ames et al 1999]. These changes were specific for the arterial
side of the circulation. As yet the physiological role of urotensin II, especially the
vasomotor response to urotensin II, in man is unknown. In contrast, vasopressin has
been extensively studied in man and animals providing a positive control to which a
novel peptide could be compared. However, some aspects of the underlying
pharmacology of vasopressin responses are not fully understood and the use of selective
vasopressin receptor antagonists may help clarify this. This will be ofparticular interest
as vasopressin receptor antagonists are now in stage 3 clinical trials for patients with
heart failure and end stage cirrhosis.
Validated methods such as venous occlusion plethysmography to measure forearm blood
flow, pulse wave analysis to assess arterial stiffness, the Aellig technique for venous
tone and laser Doppler assessment of skin blood flow provide excellent human in vivo
methods to examine novel vasoactive peptides. The following hypothesis will be
explored regarding urotensin II and vasopressin.
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1. Urotensin II will cause arterial vasoconstriction in the human forearm and, when
given in systemic doses, change haemodynamic parameters. Anticipated effects include
an increase in blood pressure, peripheral vascular resistance and arterial stiffness.
2. Vasopressin will cause arterial vasoconstriction in the human skin microcirculation
and forearm at low intra-arterial doses and cause nitric oxide mediated vasodilatation in
the forearm at high intra-arterial doses.
3. Selective vasopressin VI receptor antagonism will abolish vasoconstriction in the skin
and forearm and enhance vasodilatation in the forearm. Selective V2 receptor
antagonism will attenuate forearm vasodilatation.
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1.4 AIMS
The aims of the thesis were:
(Chapter 3). To determine the intra- and inter-operator repeatability of saline injection
volume and to assess repeatability of skin blood flow responses to intra-dermal injection
of saline.
(Chapter 4). In healthy volunteers, to undertake the first human in vivo study addressing
local responses to urotensin II in arterial vessels and dorsal hand veins.
(Chapter 5). In healthy volunteers, to determine the effects of systemic intravenous
urotensin II on a range of systemic haemodynamic parameters including blood pressure
and central arterial stiffness.
(Chapter 6). In healthy volunteers, to describe the forearm vascular actions of
vasopressin to facilitate studies with vasopressin antagonists. Pharmacodynamics and
reproducibility of responses to intra-brachial vasopressin and the contribution of nitric
oxide to its vasomotor actions will be assessed.
(Chapter 7). In healthy volunteers, to use intra-dermal injection of peptides and laser
Doppler flowmetry to assess a range of vasopressin doses in comparison to endothelin-1
and to co-administer vasopressin with a VI antagonist.
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(Chapter 8). In healthy volunteers, to study the forearm blood flow responses of intra¬
arterial VI and V2 receptor antagonists before co-infusing vasopressin with the





2.1 LOCALISED VERSUS SYSTEMIC HUMAN IN VIVO VASCULAR STUDIES
During systemic administration of vasoactive drugs in man, many organs can be affected
directly and indirectly through the action of the drug as well as neurohormonal reflexes
and changes in haemodynamics. Thus, multiple systemic effects can make the change in
measurement a composite of local and systemic changes and obscuring the "true" direct
pharmacological actions of the drug. However, local vascular bed study techniques
permit more pure investigation of drug actions on the vasculature. Studymethods such
as intra-dermal drug injection combined with measurement of skin micro circulation,
localised drug intravenous infusion combined with dorsal hand vein diameter
measurement and intra-brachial drug infusion combined with bilateral venous occlusion
plethysmography provide a method of assessing the in vivo effects of a drug on human
vessels and endothelium [Benjamin et al 1995; Webb 1995], By using this technique,
the role ofnitric oxide and endothelin-1 in the maintenance ofbasal vascular tone were
first successfully demonstrated [Vallance et al 1989; Haynes et al 1994].
2.2 GENERAL
2.2.1 Ethical considerations
All subjects were recruited from a bank of healthy community volunteers held by the
Clinical Research Centre at the Western General Hospital in Edinburgh. The studies
were conducted with the approval of the local research ethics committee and the written
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informed consent of each subject. Investigations conform to the principles of the
Declaration ofHelsinki 1989.
2.2.2 General requests made to volunteers prior to a study
Subjects were asked to fast from midnight before each study and to abstain from
caffeine containing drinks, alcohol and smoking over the preceding 24 hours. Subjects
also had to be on no prescribed medication, free from significant clinical illness and not
be participating in other research.
2.2.3 Haemodynamic measurements
Blood pressure was recorded over the brachial artery in the non-infused arm at various
intervals using a validated semi-automated ocillometric sphygmomanometer (HEM
705CP, Omron, Japan) [O'Brien et al 1996]. Non-invasive estimates of cardiac index
were assessed using a validated transthoracic electrical bioimpedance technique
[Northridge et al 1990] (NCCOM3, BoMed Irvine CA, USA). Mean arterial pressure
was defined as the diastolic pressure plus a third of the pulse pressure. Systemic
vascular resistance was defined as the mean arterial pressure divided by the cardiac
output and then converted from Wood units to dynes.s.m2/cm5 on the basis that 1 Wood
unit equals 80 dynes.s.m2/cm5 made.
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2.3 FOREARM RESISTANCE VESSELS
2.3.1 Cannulation of the brachial artery
The brachial artery of the non-dominant arm was cannulated with a 27 gauge steel
needle (Coopers NeedleWorks Ltd, Birmingham, UK). Discomfort was minimised
using 1% lignocaine (Astra Pharmaceuticals Ltd., Hertfordshire, UK) as local
anaesthesia. The cannula was attached to a 16 gauge epidural catheter (Portex Ltd,
Hythe, UK) using sealing wax. Patency was maintained by infusion of saline (0.9%:
Baxter Healthcare Ltd, Thetford, UK) via a IVAC PI000 syringe pump (IVAC Ltd,
Basingstoke, UK). During all studies intra-arterial infusion rates were maintained at a
constant 1 mL/min.
2.3.2 Blood flow measurement
Blood flow was measured in the infused and non-infused arms by venous occlusion
plethysmography using mercury-in-silastic strain gauges applied to the widest part of the
forearm (Figures 2.1 and 2.2) [Webb 1995], During measurement periods, the hands
were excluded from the circulation by rapid cuff inflation of the wrist cuffs to a pressure
of 200 mmHg using E20 Rapid Cuff Inflators (D.E. Hokanson Inc, Washington, USA).
Upper arm cuffs were inflated to 40 mmHg for 10 seconds in every 15 seconds to
achieve venous occlusion and obtain plethysmography recordings. Analogue voltage
output from an EC-4 strain gauge plethysmograph (D.E. Hokanson) was processed by a
Mac Lab® analogue to digital converter and Chart™ v3.4.3 software (A.D. Instruments
Ltd, Castle Hill, Australia) and recorded onto a Macintosh Classic II computer (Apple
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Computers Inc, Cupertino, USA) (Figure 2.3). Calibration was achieved using an
internal standard of the plethysmograph.
2.3.3 Data analysis
Plethysmography data were extracted from Chart™ data files and forearm blood flows
were calculated for individual venous occlusion cuff inflations by use of a template
spreadsheet (Excel 98, Microsoft). Recordings from the first 60 seconds after wrist cuff
inflation were not used due to the variability in blood flow that this incurs [Webb 1995].
The last five flow recordings in the 3 minute measurement period were calculated and
averaged for each arm. To reduce the variability ofblood flow data, the ratio of flows in
the two arms was calculated for each time point, thus using the non-infused arm as a
contemporaneous control for the infused arm [Benjamin et al 1995; Webb 1995],
Percentage change in the infused arm blood flow were calculated as follows:
% Change in forearm blood flow ratio = 100 x {It/NIt - Ib/NIb} / Ib/NIb
Where lb and Nib are the infused and non-infused forearm blood flows at baseline




Forearm venous occlusion plethysmography: overall set up.
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Figure 2.2
Forearm venous occlusion plethysmography: brachial artery cannulation.
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Figure 2.3









2.4.1 Laser doppler flowmetry
An accurate estimate ofblood flow in the skinmicrocirculation can be assessed using
this validated method [Kubli et al 2000], Measurement of skin blood flow depends on
the principle of the Doppler shift of laser light backscattered from moving red blood
cells in the skin microcirculation [Holloway et al 1977].
2.4.2 Drug administration
Drugs were delivered by intra-dermal injection using a graduated syringe with a 29.5
gauge needle (Becton-Dickinson, Dublin, Ireland). All drugs were administered in
standardised 10 pL volume that causes minimal discomfort to the volunteers.
2.4.3 Measurement of skin blood flow
Skin blood flow was recorded from the volar aspects ofboth forearms. Sites were
selected with care to avoid underlying arteries (as assessed by a pulsatile doppler signal)
or veins (as assessed by a high baseline doppler signal). Usually four sites on each
forearm could be selected and a probe holder attached to the skin with adhesive tape to
ensure no probe movement during the study (Figure 2.4). Biological zero recordings
were made at each site during inflation of a blood pressure cuff to 200 mmHg and after 5
minutes rest, baseline recordings were taken for the same sites. Following intra-dermal
drug injections recordings were made at each site for 30 seconds. Analogue voltage
output from a laser source (Laser Blood Flow Monitor MBF3D, Moor Instruments,
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Devon, UK) and P2 Laser Probe (Moor Instruments, Devon, UK) was processed by a
Mac Lab® analogue to digital converter and Chart™ v3.4.3 software (A.D. Instruments
Ltd, Castle Hill, Australia) (Figure 2.5), and recorded onto a Macintosh Classic II
computer (Apple Computers Inc, Cupertino, USA). Calibration was achieved using a
flux standard solution ofmicro-spheres (Moor Instruments Ltd, Devon, UK).
2.4.4 Data analysis
The mean signal values for sequential 30 second time points were extracted from
Chart™ files and applied to a spreadsheet (Excel 98; Microsoft) and a curve generated




Skin micro-circulation: whole set up.
39
Figure 2.5
Skin micro-circulation: Typical Chart™ recording.
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2.5 PULSE WAVE ANALYSIS
2.5.1 Principles of Pulse Wave Analysis
The arterial wave form that travels down the arterial tree, initiated at the start of systole,
is reflected back principally by the resistance arterioles. While the wave form is known
to alter as it progresses down the arterial tree, the profile of the wave form in the most
proximal aorta influences the left ventricular afterload and coronary blood flow.
Augmentation index is a measure ofhow much the reflected wave contributes to the
initial systolic wave. Normally when arteries are compliant the reflected wave returns in
diastole enhancing diastolic blood pressure and coronary flow. However, if the reflected
wave returns from a more proximal site in the arterial tree (such as stiffened large
arteries) and with greater velocity, it can arrive earlier in systole which augments
systolic rather than diastolic blood pressure, increasing left ventricular afterload and
reducing coronary flow [Nichols and O'Rourke 1998; Oliver and Webb 2003]. By
measuring augmentation index a composite measure of central arterial stiffness can be
obtained, whereas aortic pulse wave velocity examines the contribution of large arterial
stiffness [Nichols and O'Rourke 1998; O'Rourke 2001].
2.5.2 Measurement ofAugmentation index
Augmentation index was measured via applanation tonometry with a high fidelity
micromanometer (SPC-301; Miller Instruments, Texas, USA) over the radial artery,
where it lies anterior to the distal radius. Data were collected on to a portable computer
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and allowed quality of the recordings was assessed to ensure freedom from artefacts.
Recordings with systolic and diastolic variability in excess of 5% were excluded and the
measurement repeated. After 20 sequential waveforms have been acquired the
integrated software was used to generate an average peripheral and central waveform,
calibrated against brachial blood pressure, which was subject to further analysis to
determine augmentation index (Figure 2.6) (SphygmoCor 2000 version 6.2; PWV
Medical PTY Ltd, Sydney, Australia). Augmentation index was defined as the distance
between the first and second peaks of the central waveform, expressed as a percentage of
the pulse pressure. All measurements were made in duplicate and mean values used in
subsequent data analysis. Recordings with systolic and diastolic variability in excess of
5% were excluded and the measurement repeated.
2.5.3 Measurement of Aortic Pulse Wave Velocity
Pulse wave velocity (PWV) was determined using electrocardiographic monitoring
combined with pulse wave analysis (SphygmoCor 2000 version 6.2) at the carotid artery
(adjacent to the thyroid cartilage) and femoral artery (immediately below the inguinal
ligament). The separation of the pulse waveforms was defined as the distance between
the sternal notch and both the inguinal ligament and the thyroid cartilage. All
measurements were made in duplicate and mean values used in subsequent data analysis.
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Figure 2.6









Aortic Blood Pressure Report
Address :
STUDY DATA
04 Dec 2000,17:07:30 Operator ID:
Medication:
Notes: U007b sal 22-30
CENTRAL HAEMODYNAMIC PARAMETERS
Heart Rate. Period 68 bpm, 1031 ms PI Heigh((P1 - Dp) 32 mmHg Buckberg SEVR (Ad/As) 172% (3663/2133)
Ejection Duration (ED) 340 ms, 33% Augmentation (AG) 4 mmHg MP. (Systole. Diastole) 108, 91 mmHg
Aortic T1.T2, Tr 146,227,192 ms Aug. Index (AG/PP, P2/P1) n%. 112% End Systolic Pressure i07mmHg
QUALITY CONTROL
Pulse Height 125
Pulse Height Variation 3%
Diastolic Variation 3%
Pulse Length Variation 2%
dP/d! Max 634
PWV Medical SC0K-?IX)a E.2 (00216) 110 DATA tM Dee 2C00
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2.6 HAND VEIN STUDIES
2.6.1 Venous displacement technique and venous cannulation
Studies were carried out using a standard displacement technique [Aellig 1981; Webb
and Haynes 1993]. During studies subjects were seated on a bed with hand and arm of
the measured vein placed on an arm rest above the level of the heart. A 23 gauge
butterfly® cannula (Abbott, Sligo, Ireland) was placed in a 2 cm length ofnon-branching
dorsal hand vein in the direction ofblood flow and attached to a 16 gauge epidual
catheter (Potex Portex Ltd, Hythe, UK). Patency was maintained by infusion of saline
(0.9%: Baxter Healthcare Ltd, Thetford, UK) via a IVAC PI000 syringe pump (IVAC
Ltd, Basingstoke, UK) at a rate of 0.25 mL/min. A tripod was placed 1.5 cm proximal
to the cannulation site, ensuring it was not overlying any other veins. The tripod
supported a linear variable differential transformer, the central bar of which rested on the
apex of the chosen vein. The total infusion rates were kept constant at 0.25 mL/min
throughout studies.
2.6.2 Measurement of venous tone
Measurements were made every 5 minutes during which a cuff is inflated intermittently
to 30 mmHg using an E20 Rapid Cuff Inflator (D.E. Hokanson Inc, Washington, USA),
thus occluding venous outflow in the studied arm. Analogue voltage, generated by
displacement of the central rod in the tripod (Figure 2.7), was processed by a Mac Lab®
analogue to digital converter and Chart™ v3.4.3 software (A.D. Instruments Ltd, Castle
Hill, Australia) and recorded onto a Macintosh Classic II computer (Apple Computers
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Inc, Cupertino, USA). The difference between the voltage recorded during inflation and
deflation of the cuff is a measure of the diameter of the studied vein [Aellig 1981].
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Figure 2.7
Aellig hand vein technique: tripod setup [Aellig 1981].
Deflated cuff Inflated cuff (30mmHg)
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2.7 BLOOD COLLECTION AND PEPTIDE ASSAY
2.7.1 Forearm venous sampling
Venous cannulae were inserted into large subcutaneous veins of the anticubital fossa in
both arms as previously described [Plumpton et al 1995]. Blood was withdrawn
simultaneously from each arm during the last 2 min of each infusion. Samples for
urotensin II estimation were collected in tubes containing ethylene diamine tetra-acetic
acid (EDTA) tubes (Monovette®, Sarstedt, Numbrecht, Germany). Samples were
centrifuged at 3,000 g for 10 min at 4°C and the plasma stored at -80°C until subsequent
analysis.
2.7.2 Urotensin II assay
Plasma human urotensin II (hUII) concentrations were determined by radioimmunoassay
using rabbit anti-flounder urotensin II antibody and human urotensin II iodinated by the
Iodogen method of Fraker and Speck [Fraker and Speck 1978]. The antibody had equal
specificity for human and flounder UII, and there was no cross-reactivity in the assay
with endothelin-1, angiotensin II or somatostatin-14 (Sigma Chemical Co, UK). Before
assay, plasma samples were subject to reverse-phase chromatographic purification using
Sep-Pak CI8 cartridges (Millipore UK Ltd) with acetonitrile solvent. The assay
protocol was based on that previously described for flounder urotensin II [Winter et al
1999], Briefly, sample extract was incubated with antibody (38,400 dilution) and 125I
human urotensin II at 4°C for 24 hours. Following this, the complexes formed were
precipitated by the addition of bovine v-globulin (Sigma Chemical Co, Dorset, UK) and
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polyethylene glycol (Sigma Chemical Co, Dorset, UK), and the bound fraction was
counted for 10 min in a gamma counter (1275 minigamma, Wallac, Finland). A typical
standard curve for the human radio-immunoassay is shown in Figure 4.1. Also shown is
the parallelism of serial dilutions of human plasma extract with the standard curve
established for synthetic human urotensin II, confirming the specificity of the assay and
its suitability for measurement of plasma human urotensin II. Recovery ofhuman
urotensin II in plasma extracts was 63% and intra- and inter-assay coefficients of
variation in our laboratory were 7.6% and 13.3% respectively; the sensitivity of the
assay was 1 fmol/mL.
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CHAPTER 3
VALIDATION OF LASER DOPPLER FLOWMETRY COUPLED WITH
INTRA-DERMAL INJECTION
SJ Leslie, JT Affolter, MA Denvir, DJ Webb. Validation of laser Doppler flowmetry
coupled with intra-dermal injection for investigating effects of vasoactive agents on the
skin microcirculation. Eur J Clin Pharm 2003;59:99-102.
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3.1 SUMMARY
We aimed to determine the repeatability and reproducibility of laser Doppler flowmetry
coupled with intra-dermal saline delivery. Two operators each performed 100
injections. Delivery of saline was judged 'by eye' using a graduated syringe (Becton-
Dickinson) by injecting onto a weighing boat. Saline volume of 10p,L was assessed by
weight were 1 g = 1 mL saline. Skin blood flow following intra-dermal injection of
saline was assessed in 18 healthy volunteers; 10 attended twice to assess between-day
reproducibility, and 8 attended once to assess between-site repeatability. Results are
expressed as mean value and 95% confidence interval for mean differences. There was
no difference in mean injection weight between operators, both being 10.3 ±0.1 mg
(0.08, -0.23 to 0.39 mg: mean difference, 95% confidence, n=100, P=0.9). Intra-dermal
delivery of saline was well tolerated with only mild discomfort experienced during the
injection at some of the sites. Intra-dermal saline caused a 9-fold increase in skin blood
flow (P0.001). This response was rapid in onset with the maximal effect seen at 4 min
and apparent duration of greater than 30 min. There was no difference in the magnitude
of the response between the dominant and non-dominant arms, the area under the curve
being 2.9 ± 0.4 perfusion units (PU) for both (-0.05, -0.8 to 0.73 PU: mean difference,
95% confidence, n=l 8, P=0.9). There was no statistical difference between study visits 1
and 2, area under the curve was 3.2 ± 0.6 and 2.0 ± 0.5 PU respectively (1.2, 0.03 to
2.43 PU: mean difference, 95% confidence, n=10, P=0.7). There was no difference in
the magnitude of responses between different sites on the forearm (P=0.6). These
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studies demonstrate that the technique of laser Doppler flowmetry coupled with intra¬
dermal injection is a safe, well-tolerated technique with good repeatability. A trend
towards reduced between-day reproducibility emphasises the importance of vehicle
control sites when investigating the effects of vasoactive compounds. This technique
provides a reliable method for the intra-dermal delivery of the potential drug vehicle
saline, despite the direct effect of injection of saline on blood flow.
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3.2 INTRODUCTION
Laser Doppler flowmetry is a well validated technique [Nilsson et al 1980] used for the
investigation of the effects of vasoactive substances on the skin microcirculation [Hovell
et al 1987; Haynes et al 1991; Wenzel et al 1994). Saline is widely used as vehicle for
drug administration in other vascular beds and it has been previously demonstrated that
intra-dermal injection of saline, when used alone, causes an increase in laser Doppler
flowmeter signal [Wenzel et al 1994]
Laser Doppler flowmetry coupled with intra-dermal injection has several potential
advantages over other techniques for the initial study of drugs in humans in that it is
minimally invasive and relatively safe because it uses very small doses of study
compound with a mainly local activity. It also allows separate sites on the skin to be
studied simultaneously and thus the investigation of a range of concentrations on the
same study visit.
While it is possible to deliver some vasoactive substances such as acetylcholine and
noradrenaline by skin iontophoresis, many peptides cannot be delivered by this means
due to their large size, poor solubility or lack of electrical charge. In these situations,
intra-dermal injection can be used. However, this technique has the theoretical
disadvantage that it results in a small degree of skin trauma [Holloway 1980] and
delivery of small volumes may increase errors and variability in responses.
Physiological saline is commonly used in studies as a drug vehicle and there are a
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variety of high precision syringes, which can be used for the intra-dermal injection.
However, these are expensive and when used in human studies can, by necessity, be
used only for a single subject. In the current studies we used standard clinical insulin
syringes with a 29.5 SWG gauge needle to administer intra-dermal injections. The
advantages of these syringes are that they are relatively inexpensive and easy to use.
These syringes have been used by others in SBF studies [Wenzel et al 1994, 1996 and
1998] but have not been validated for use for intra-dermal injection in pharmacological
studies. There are potential sources of error in the injection technique because the
plunger is depressed by only 1 mm to deliver 10 pi and is judged 'by eye'. The
repeatability of intra-dermal delivery in terms of volume delivered and the effect of
intra-dennal saline injection on skin blood flow has not previously been reported.
The aim of these studies was to determine the intra- and inter-operator repeatability and
reproducibility of saline administration in terms of injection volume and to determine




Eighteen healthy men (22-45 years, all right handed) were studied. Studies were
performed with the approval of the local research ethics committee and in accordance
with the Declaration ofHelsinki of the World Medical Association. Written informed
consent was obtained from each subject before entry to the study. None of the subjects
were taking regular medication and all avoided any medication for 1 week prior to the
study. All subjects abstained from alcohol for 24 hours and from food, tobacco and
caffeine containing drinks for at least 12 hours before each study.
3.3.2 Injection volume
Graduated 29.5 SWG syringes (Becton-Dickinson, Dublin, Ireland) were used for saline
delivery. Each 1 mm graduation on the 0.5 mL syringe represents 10 pL, thus to deliver
this volume the syringe plunger was depressed by 1 mm. The repeatability of injection
volume was assessed by injecting 10 pL saline judged by depressing the syringe plunger
by one graduation, onto a weighing boat placed on a balance (Mettler Toledo® MT5).
This balance has an accuracy and precision of 1 pg and therefore can measure changes
of 1 nL assuming a specific gravity of saline (0.9%; Baxter Healthcare Ltd, Thetford,
UK) of 1.00. A new syringe was used for each injection and care was taken, as in our
clinical studies, to expel any air bubbles from the syringe before injecting. The balance
was set to zero before each injection. Two operators each performed 100 injections.
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3.3.3 Study design
Studies were performed in a quiet temperature controlled, draught free room (22-24°C).
Each subject was allowed to rest for at least 20 min before the study protocol was
started. Baseline recordings were made and then volunteers received intra-dermal
injections of 10 pL 0.9% saline. Following intra-dermal injection, laser Doppler signal
was recorded every 2 min until 10 min and every 5 min until 30 min. To assess
between-day reproducibility, 10 subjects attended for 2 study visits. To assess between-
site repeatability, 8 of the subjects received 4 intra-dermal injections of saline on the
volar aspect of each forearm.
3.3.4 Data analysis
Increases in weight on the balance following saline injection were recorded manually
and entered onto a spreadsheet (Excel v5.0; Microsoft). The accuracy was assessed by
mean values, and reproducibility by assessing the spread of results. Results are
expressed as mean ± SEM perfusion units (PU). Differences between results were
compared using Student's /-test. Statistical significance was taken at the 5% level.
Calculated area under the curve results were assessed using the method ofBland and
Altman [Bland & Altman 1986], Bland-Altman analysis allows the assessment of
agreement and systematic bias. Coefficients of repeatability were determined for 95%
confidence intervals. Statistical analysis was performed using Student's /-test and single





Two operators performed 100 injections each. There was no difference in mean
injection weight between operators, both being 10.3 ±0.1 mg (figure 3.1, mean
difference 0.08, 95% confidence intervals -0.23 to 0.39 mg, n=T00, P=0.9).
3.4.2 Tolerability of intra-dermal saline
The technique was well tolerated by subjects with only mild discomfort experienced
during the injection of saline at some of the sites. This discomfort was variable in
intensity. In the majority of cases the trauma from intra-dermal injection did not leave
any discernible mark on the skin by the end of the study although several injections did
cause a small degree ofbleeding along the track of the needle. This did not appear to
affect the results in terms of repeatability.
3.4.3 Skin blood flow responses: effect of intra-dermal injection of saline
Saline caused a 9-fold increase in skin blood flow (0.03 ± 0.003 to 0.27 ± 0.02 PU,
n=l 8, P0.001). This effect was rapid in onset with maximal response seen at 4 min,
see figure 3.2.
3.4.4 Between-arm repeatability
There was no difference in magnitude of response between dominant and non-dominant
arms, area under the curve was 2.9 ± 0.4 PU for both (figure 3.2, mean difference -0.05,
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95% confidence intervals -0.8 to 0.73 PU, n=18, P=0.9). Bland-Altman analysis was
performed demonstrating no systemic bias and a co-efficient of repeatability of 3.54 PU
(figure 3.5).
3.4.5 Within-subject same-day repeatability: Between-site repeatability
Area under the curve was constructed for the responses at 4 different sites on each
forearm in 8 subjects. There was no difference in the magnitude of responses between
sites on the forearm as assessed by area under the curve (figure 3.4, ANOVA, P=0.6).
3.4.6 Between-day reproducibility
There was a trend towards a difference between study visits 1 and 2, area under the
curve was 3.2 ± 0.6 and 2.0 ± 0.5 PU respectively (1.2 mean difference, 95% confidence
intervals 0.03 to 2.43 PU, n=10, P=0.7) although this did not reach statistical
significance (figure 3.3). Bland-Altman analysis was performed demonstrating no




Observer 1 Observer 2
Figure 3.1




Effect of intra-dermal saline on SBF between dominant (O) and non-dominant (•)
arm on the same study visit. Mean ± SEM.
Figure 3.3
Time (min)
Effect of intra-dermal saline on SBF on the dominant arm on the different
study visits 1 (•) and 2 (O). Mean ± SEM.
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Figure 3.4
Simultaneous effect of intra-dermal saline injection on SBF between 8 sites
on the same day. Sites 1-4 were chosen on the dominant arm (numbered
proximal to distal on forearm), sites 5-8 were chosen on the non-dominant
















































Bland and Altman plot for between-day reproducibility.
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3.5 DISCUSSION
In this study we have demonstrated that saline delivery using the Becton-Dickinson
syringe is accurate and repeatable with low intra-operator and inter-operator variability.
In addition, we have demonstrated that intra-dermal injection of saline causes an
increase in Doppler signal but that the magnitude of this increase is similar between
different sites on the forearm. There is good within-day and between arm repeatability.
There was occasionally mild discomfort experienced by the subjects at the time of
injection. However, there did not appear to be any pattern to explain the fact that some
sites developed more discomfort than others. Although the non-uniform distribution of
cutaneous nerves may explain this finding, this was not formally assessed and did not
appear to affect the results in terms of repeatability.
While there is often greater interest in the systemic effects of vasoactive compounds,
there are potential risks with administration of systemic doses of vasoactive compounds.
The use of local techniques, such as intra-dermal administration with laser Doppler
microcirculatory blood flow measurement has allowed the relatively safe observation of
the in vivo effects of vasoactive compounds, without causing confounding compensatory
systemic effects. While the skin blood flow is under different regulatory mechanisms
and responses can differ from other vascular beds [Weber et al 1997], the effects of
compounds in the skin have been generally reflected in other less accessible vascular
beds [Wenzel et al 1994; Wenzel et al 1995]. Therefore the assessment of skin
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microcirculation changes following intra-dermal injection can offer a safe, well
tolerated, easy to use method to the initial investigation of vasoactive compounds.
Most vasoactive compounds will be prepared in saline for dose ranging studies. Some
may be delivered to the skin by iontophoresis, however, this is not suitable for many
compounds due to their large size and relative insolubility. Intra-dermal injection of
study compounds is employed in these cases.
The Becton-Dickinson syringe is commonly used to delivery intra-dermal injections in
clinical practice. Although it has the advantage that it is inexpensive and easy to use, its
accuracy has not previously been described. Here, we found good agreement between
operators as seen bymean values that were similar and close to the intended volume of
10 pL with most injections very close to this volume (figure 3.1). We conclude that this
syringe can be used to deliver intra-dermal injections in a clinical research setting with
sufficient accuracy and repeatability.
Intra-dermal saline causes an increase in laser Doppler signal. In this study, we have
demonstrated that the technique of laser Doppler flowmetry coupled with intra-dermal
injection is a repeatable method and that responses between subjects were similar.
There was no difference in skin blood flow in response to intra-dermal saline injection
between sites on the same arm or in the same subject on different study visits. This
indicates the importance of employing saline placebo controls for all studies using intra¬
dermal injections. There was, however, a trend towards a small difference in skin blood
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flow between study visits which emphasises the importance of a vehicle control site
when investigating vasoactive compounds. The reasons for this between-day variability
are not clear as ambient temperature was controlled, subjects were fasted and under
similar conditions during each study visit. Although careful attempts were made to keep
room temperature and conditions constant, the skin is more sensitive than other vascular
beds to changes in ambient conditions and small temperature changes, draughts or
emotional factors may be more important than in other vascular beds. Nevertheless,
these apparent between day differences did not reach statistical significance and the
within-subject and between-day coefficients of repeatability were similar. We conclude
that despite small difference between days that vehicle control injections should be
performed during each study visit.
In conclusion, the technique of intra-dermal injection coupled with laser Doppler
flowmetry offers a safe, well-tolerated, repeatable technique for the potential
investigation of vasoactive compounds using saline as a drug vehicle in human in vivo.
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CHAPTER 4
HUMAN UROTENSIN II LOCAL VASCULAR STUDIES IN MAN
IB Wilkinson, JT Affolter, SL De Haas, MP Pellegrini, J Boyd, MJ Winter, RJ Balment
and DJ Webb. High plasma levels of urotensin II do not alter local or systemic
haemodynamics in man. Cardiovascular Research 2002;53:341-347.
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4.1 SUMMARY
Human urotensin II is an endocrine hormone that acts as a potent arterial vasoconstrictor
in in vitro and in vivo studies in animals. We examined, for the first time, the local and
systemic haemodynamic response to urotensin II in man in vivo. Four healthy male
volunteers took part in pilot studies and 11 in definitive studies. Forearm blood flow
was measured in response to intra-arterial infusion of authentic, biologically active
urotensin II (incremental rates of 0.001-300 pmol/min) and saline placebo using venous
occlusion plethysmography. Blood pressure, heart rate, cardiac output and urotensin II
plasma concentrations were also measured. Forearm studies were repeated in 5 subjects
with inhibition of endothelial mediators using aspirin and a 'nitric oxide clamp'. Dorsal
hand vein diameter was determined by a standard displacement technique in response to
local administration of urotensin II (3-300 pmol/min) with and without nitric oxide
synthase inhibition. There was no significant change in forearm blood flow
during brachial infusion of saline or urotensin II (dose range, 0.001 to 300 pmol/min).
A nitric oxide clamp did not unmask vasoactive effects of urotensin II infusions (100
and 300 pmol/min) significantly increased plasma concentrations from baseline (12 ± 3
pmol/mL) to 106 ± 15 and 307 ± 98 pmol/mL respectively. Despite high circulating
urotensin II concentrations, no change was seen in systemic haemodynamics and ECGs
were unchanged. Human urotensin II had no effect on hand vein diameter (n=6). In
contrast to our hypothesised role of urotensin II, we found no vasoactive responses to
urotensin II in vivo, consistent with recent in vitro studies in human blood vessels but in
contrast to non-human primate studies in vivo. Our data do not support a key role for
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urotensin II in the regulation of vascular tone and resting blood pressure in man.
However, studies with urotensin II receptor antagonists are also needed before firm
conclusions can be drawn.
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4.2 INTRODUCTION
Human urotensin II is a recently discovered vasoactive peptide hormone that acts as a
high affinity ligand for rat G-protein receptor 14 (GPR14) [Coulouarn et al 1997; Ames
et al 1999; Nothacker et al 1999] and the more recently discovered human receptor
[Nothacker et al 1999], It is the most potent arterial vasoconstrictor yet discovered and
has a sustained effect in blood vessels from a variety of species [Ames et al 1999;
Maguire et al 2000; MacLean et al 2000],
Human urotensin II was first isolated in man from subgroups ofmotor neurones in the
spinal cord [Coulouarn et al 1997]. Outwith the CNS, the kidney has the highest
expression of prepro urotensin II mRNA and, therefore, appears the most likely source
of circulating urotensin II receptor [Nothacker et al 1999], Its receptor distribution has
been mapped using immuno-histochemistry, confirming target binding sites for
urotensin II in cardiovascular tissues including coronary arteries, internal mammary
arteries and ventricular cardiomyocytes [Ames et al 1999; Maguire et al 2000]. Thus, it
is likely that circulating urotensin II functions as an endocrine hormone. In vitro animal
data and studies in rats and non-human primates in vivo, indicate that urotensin II is a
potent vasoconstrictor and influences cardiac function [Ames et al 1999; Maguire et al
2000]. However, conflicting results have been obtained from human blood vessels in
vitro [Maguire et al 2000; MacLean et al 2000; Stirrat et al 2001]. Although some
studies suggest that urotensin II is 28 to 50 fold more potent than endothelin-1 [Ames et
al 1999; Maguire et al 2000], others show urotensin II to be a vasodilator [Stirrat et al
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2001], In addition, there is some variability in response to urotensin II amongst species
[Douglas et al 2000], depending on vessel location and type, and between individual
preparations. This is highlighted by some of the in vitro studies having responding and
non-responding vessels [MacLean et al 2000], Interestingly, in the rat, the activity of
urotensin II is most marked in the region of the proximal aorta, decreasing rapidly
further down the arterial tree [Maguire et al 2000], Venoconstriction has been found
only in some studies in vessels from non-human primates and humans and, in contrast to
the effects of endothelin-1 and norepinephrine, and where present, urotensin II is less
potent in veins than arteries [Ames et al 1999; Maguire et al 2000].
To date, there have been no in vivo physiological studies of the actions of urotensin II in
man. On the basis of animal in vivo and the positive human in vitro studies, we
hypothesised that urotensin II would cause arteriolar vasoconstriction in the human
forearm, but have little or no effect in veins. We also anticipated that systemic dosing
would raise peripheral resistance and, hence, blood pressure. Our aim was to undertake
the first human in vivo study with urotensin II, addressing local responses in human
arterial vessels and dorsal hand veins. Subsequently, we explored the effect of higher




These studies were conducted with the approval of the local research ethics committee
and the written informed consent of each subject. The investigation conforms to the
principles of the Declaration of Helsinki. Fifteen healthy men, mean age 37 ± 4 years
(range 22-53), were recruited from a bank of community volunteers held by the Clinical
Research Centre at the Western General Hospital in Edinburgh. Four subjects took part
in pilot studies and eleven in the definitive vein and forearm studies. Subjects were
asked to fast from midnight before each study, and to abstain from caffeine containing
drinks, alcohol and smoking over the preceding 24 hours. Subjects mean height was 176
±3 cm (range 170-180) and mean weight was 80 ± 8 kg (range 63-92).
4.3.2 Drugs
All drugs were freshly prepared aseptically and dissolved in either saline (0.9% Baxter
Healthcare Ltd., Norfolk, UK) or Gelofusine® (Braun Healthcare Ltd., Sheffield, UK).
The drugs used were: human urotensin II (Peptide Institute, Osaka, Japan and
SmithKline Beecham, Pennsylvania, USA), angiotensin II (ANGII; Clinalfa,
Laufelfmgen, Switzerland), norepinephrine (NE; Abbott Laboratories, Kent, UK),
sodium nitroprusside (SNP; David Bull Laboratories, Warwick, UK) and L-N°-
monomethylarginine (L-NMMA; Clinalfa).
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We confirmed the authentic nature of the human urotensin II from both sources by high
performance liquid chromatography and microsequencing (in the laboratory of Drs. S.A.
Douglas and E.H. Ohlstein, SmithKline Beecham). We also confirmed the biological
activity of the urotensin II peptides by showing the anticipated responses, and potency,
in the rat proximal aorta.
4.3.3 Study design
Saline was infused at 1 ml/min for a period of 30 min before drug infusion protocols
were started to ensure a stable baseline. The total infusion rate was kept constant at 1
ml/min. Throughout the study forearm blood flow was measured simultaneously in both
arms by venous occlusion plethysmography [Whitney 1953; Benjamin et al 1995;
Wilkinson and Webb 2001], as previously described [Love et al 1996], Forearm blood
flow was measured over a 3 min period every 6 min, and the last five recordings of
forearm blood flow were averaged to determine flow in each arm. Cardiac index was
assessed using a validated [Northridge et al 1990] transthoracic electrical bioimpedance
technique (NCCOM3, BoMed Irvine CA, USA). Both blood pressure and cardiac index
were recorded after each forearm blood flow recording was completed. Mean arterial
pressure was defined as diastolic pressure plus 1/3 of the pulse pressure. Peripheral
vascular resistance was calculated as mean arterial pressure divided by cardiac index and
expressed in arbitrary units. Throughout the study continuous electrocardiographic
(ECG) monitoring was employed and a full 12 lead ECG recorded at baseline and at the
end of the highest urotensin II infusion rate on each study day.
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4.3.4 Pilot studies
Human UII (Peptide Institute, Osaka Japan), diluted in 0.9% saline vehicle was given
intra-arterially on 3 separate occasions, each in 2 subjects, at rates of 0.001, 0.003 and
O.Olpmol/min, 0.03, 0.1 and 0.3pmol/min, and 1, 10 and 30pmol/min. After 30 min
saline run-in, each dose ofurotensin II was given for 20 min.
4.3.5 Local arterial and systemic haemodynamics (Study 1)
On two occasions, separated by one week, each subject received a 30 min infusion of
saline and then either urotensin II (Peptide Institute, Osaka Japan) or saline in a single-
blind, randomised manner. Four subjects received 30 and lOOpmol/min urotensin II, and
6 subjects 100 and 300pmol/min urotensin II. Each rate was maintained for a total of 20
min and forearm blood flow recorded at 3, 9 and 15 min. After the final forearm blood
flow recording during saline baseline infusions and each dose increment, systemic
haemodynamic measurements were made (heart rate, blood pressure and cardiac index)
and lOmL of venous blood was collected for determination of plasma urotensin II
concentration. In addition, forearm blood flow studies were repeated in some of the
same subjects. First, we used an alternative batch of urotensin II (SmithKline Beecham,
Pennsylvania, USA; dose range 0.1, 1, 10, 30pmol/min: 6 subjects). Second, we used an
alternative Gelofusine® vehicle with the original urotensin II (Peptide Institute, Osaka
Japan; dose range 1, 3, 30, 300pmol/min: 4 subjects).
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4.3.6 Local arterial haemodynamics with inhibition of endothelial mediators
(Study 2)
Five of the subjects who took part in study 1 underwent a further study involving a
'nitric oxide clamp' [Verhaar et al 1998]. First, saline was infused for 30 min, and
followed by L-NMMA infused intra-arterially at 4pmol/min to block endogenous nitric
oxide generation [Vallance et al 1989]. Forearm blood flow was then restored to within
± 10% of baseline by the co-infusion of SNP, an endothelium-independent nitric oxide
donor (mean dose 0.6 nmol/min, range 0.3-1.0). To produce a simultaneous inhibition
of prostanoid production, each subject received 600mg aspirin dissolved in 200 ml of
water 30 min before the study. At this dose aspirin inhibits bradykinin-stimulated
endothelial prostacyclin generation and platelet thromboxane production [Heavey et al
1985], but has no direct effect on blood pressure or basal vascular tone. Once forearm
blood flow had returned to basal levels, urotensin II was co-infused at 1, 10 and 100
pmol/min, each rate for 20 min. Forearm blood flow and systemic haemodynamics were
recorded as for Study 1.
4.3.7 Venous tone (Study 3)
Six subjects made two visits, separated by one week. Each received a 30 min infusion of
saline into a selected dorsal hand vein followed by either L-NMMA (100 nmol/min) or
saline in a single-blind, randomised manner for 5 min. Human urotensin II was then co-
infused at 3, 30 and 300 pmol/min, each rate for 20 min. Saline was then infused for 10
min, followed by ANGII (25 ng/min) for 3 min then saline for a further 10 min and
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finally NE (8 ng/min) for 3 min to assess the integrity of the vein. Hand vein diameter
was measured every 5 min after a 10 min baseline saline infusion. The total infusion
rate was kept at 0.25 mL/min.
4.3.8 Plasma urotensin II concentrations
Venous blood (10 mL) was drawn during the last 2 min of each infusion period from a
cannula sited in the non-infused arm. Samples were collected into ethylene diamine
tetra-acetic acid, immediately centrifuged at 3,000 g for 10 min at 4°C and the plasma
stored at -80°C until subsequent analysis. Plasma human urotensin II concentrations
were determined by radioimmunoassay using rabbit anti-flounder urotensin II antibody
and human urotensin II iodinated by the Iodogen method of Fraker and Speck [Fraker
and Speck 1978]. The antibody had equal specificity for human and flounder urotensin
II, and there was no cross-reactivity in the assay with endothelin-1, angiotensin II or
somatostatin-14 (Sigma Chemical Co, UK). Before assay, plasma samples were subject
to reverse-phase chromatographic purification using Sep-Pak CI8 cartridges (Millipore
UK Ltd) with acetonitrile solvent. The assay protocol was based on that previously
described for flounder UII [Winter et al 1999], Briefly, sample extract was incubated
with antibody (38,400 dilution) and 125I human urotensin II at 4°C for 24h. Following
this, the complexes formed were precipitated by the addition of bovine v-globulin
(Sigma Chemical Co, UK) and polyethylene glycol (Sigma Chemical Co, UK), and the
bound fraction was counted for 10 min in a gamma counter (1275 minigamma, Wallac,
Finland). A typical standard curve for the human urotensin II radio-immunoassay is
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shown in Figure 4.1. Also shown is the parallelism of serial dilutions of human plasma
extract with the standard curve established for synthetic human urotensin II, confirming
the specificity of the assay and its suitability for measurement of plasma human
urotensin II. Recovery of human urotensin II in plasma extracts was 63% and intra- and
inter-assay coefficients of variation in our laboratory were 7.6% and 13.3% respectively;
the sensitivity of the assay was 1 frnol human urotensin II mL plasma.
4.3.9 Statistical analysis
All results are expressed as mean ± SEM. Data for FBF has been expressed as a
percentage change from baseline of the FBF ratio (derived from infused arm value
divided by non-infused arm value). Repeated measure ANOVA was used to identify
differences in FBF response between urotensin II and saline, urotensin II concentrations
during placebo and drug infusion and in the vein studies between presence and absence
of urotensin II and L-NMMA co-infusion. For single comparisons, data were analysed
using paired Student's t-tests. Results were considered significant at P<0.05.
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4.4 RESULTS
All subjects were symptom free throughout each study. Baseline forearm blood flow,
heart rate, cardiac index, blood pressure, plasma urotensin II concentrations and vein
diameter were similar on the different study days and there was no significant difference
in the basal forearm blood flow between the infused and non-infused arms. Neither
continuous single-lead ECG monitoring, nor the full 12-lead ECGs, revealed any
changes during the 3 studies.
4.4.1 Pilot studies
There was no significant change in FBF in either arm, or systemic haemodynamics,
during infusion of saline or hUII (data not shown).
4.4.2 Local arterial and systemic haemodynamics (Study 1)
Baseline values for the non-infused and infused forearm blood flow were as follows; 3.5
± 0.9 and 4.5 ± 2 ml/100ml tissue/min respectively for Figure 4.2A and 2.9 ± 0.4 and 2.9
± 0.7 ml/100ml tissue/min for Figure 4.2B. There was no significant change in forearm
blood flow ratio during infusion of saline or urotensin II in either of the dose ranging
studies (Figures 4.2A and B). There was no significant change in systemic
haemodynamics during infusion of urotensin II at any dose (Table 4.1 A and B).
However, there was a substantial and significant increase in circulating plasma urotensin
II concentrations during urotensin II infusion (Figures 4.3A and B). Studies with
urotensin II diluted in Gelofusine® rather than saline, and urotensin II from an
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alternative supplier (SmithKline Beecham, Pennsylvania, USA), similarly did not
change forearm blood flow or systemic haemodynamics (data not shown).
4.4.3 Local arterial haemodynamics with inhibition of endothelial mediators
(Study 2)
Baseline values for non-infused and infused forearm blood flow were 3.1 ± 0.3 and 3.2 ±
0.5 ml/100ml tissue/min respectively. Infusion of L-NMMA resulted in a significant
reduction in the forearm blood flow ratio (1 ±0.1 at baseline compared with 0.6 ±0.1;
P=0.01 Student's t-test) (Figure 4.4). Co-infusion of SNP (mean dose 0.6 nmol/min,
range 0.3 to 1.0) returned the forearm blood flow ratio to baseline (1 ± 0.1 at baseline
compared with 0.8 ± 0.1, P=0.7 Student's Mest). There was no significant change in the
forearm blood flow ratio, or forearm blood flow in either arm, during co-infusion of
urotensin II following L-NMMA and SNP (forearm blood flow ratio, P=0.3). Human
urotensin II infusion did not significantly alter heart rate, systolic or diastolic blood
pressure (P=0.8, P=0.8 and P=0.3 respectively, ANOVA).
4.4.4 Venous tone (Study 3)
Increasing doses of urotensin II had no significant effect on hand vein diameter
compared with baseline (P=0.9, ANOVA) (Table 4.2). During co-infusion of urotensin
II and L-NMMA, there was also no significant change in hand vein diameter (P=0.8,
ANOVA). In contrast, ANGII and NE both induced a substantial venoconstriction (see
Table 4.2). The response to ANGII and NE was slightly higher during L-NMMA co-
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administration, but these differences from the response with L-NMMA were not
significant (P=0.8 and P=0.2 respectively, Student's r-test).
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Figure 4.1
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Figure 4.1
Typical radio-immunoassay curve for hUII, with antibody bound 125-1 hUII for
increasing standard concentrations of synthetic hUII expressed as % the maximum label
binding (Bo) measured in the zero standard tubes. Also shown is antibody bound label
for assay tubes containing serial dilutions of human plasma extract. The parallelism of




A Mean percentage change in FBF ratio during 30 and 100 pmol/min UII infusion (•)
compared with saline (□). ANOVA P=0.9 (n=4).
B Mean percentage change in FBF ratio during 100 and 300 pmol/min UII infusion (•)
compared with saline (□). ANOVA P=0.4 (n=6).
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79 ±3 98 ±4 63 ±2 3.4 ±0.2 29.4 ± 1.9
30 pmol.min"1 131 ±9 81 ± 1 98 ±3 65 ± 3 3.4 ±0.1 28.8 ± 1.7
100 pmol.min"1 133 ±7 80 ±2 98 ±3 68 ±4 3.3 ±0.1 29.7 ± 1.0
Saline 137 ± 8 82 ±4 100 ±5 66 ±3 3.2 ±0.1 31.4 ± 1.3
Results are expressed as mean values ± SEM (n=4). SBP=systolic blood pressure,
DBP=diastolic
blood pressure, HR=heart rate, CI=cardiac index, PVR=peripheral vascular resistance.
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Saline 124 ±6 75 ±6 91 ±6 63 ±4 3.7 ±0.2 24.9 ±2.5
100 pmol.min" 124 ±7 77 ±5 93 ±5 61 ±4 3.7 ±0.2 25.2 ±2.3
300 pmol.min"1 122 ±6 77 ±5 92 ±5 60 ±3 3.8 ±0.2 25.6 ±2.8
Saline 128 ±5 77 ±4 94 ±4 62 ±3 3.7 ±0.2 26.2 ± 2.2
Results are expressed as mean values ± SEM (n=4). SBP=systolic blood pressure,
DBP=diastolic blood pressure,
HR=heart rate, CI=cardiac index, PVR=peripheral vascular resistance.
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Figure 4.3
A Mean plasma concentration ofhUII during 30 and 100 pmol.min"1 UII infusion. **
P<0.01 compared to baseline saline infusion (n=4).
B Mean plasma concentration of hUII during 100 and 300 pmol.min"1 UII infusion. *
P<0.05, ** P<0.01, *** P0.001, Student's Mest compared to baseline saline infusion
(n=6).
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Figure 4.4
Mean percentage change in the FBF ratio after co-infusion of L-NMMA (4p.mol.min"1)
and co-infusion ofUII, * P=0.01 compared to baseline, Student's i-test. ANOVA for
UII response was not significant P=0.3 (n=5).
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4.5 DISCUSSION
The principal finding in these human studies in vivo is that infusion of urotensin II has
no effect on arterial or venous tone, or on systemic haemodynamics. In addition,
combined inhibition of nitric oxide and prostanoid production did not reveal any
vasoactive effects of urotensin II in the forearm arteries or dorsal hand veins. We
established the authentic nature of the urotensin II by microsequencing and by showing
that it was pharmacologically active in vitro. Furthermore, substantial and consistent
increases in plasma concentrations of urotensin II confirmed its delivery to the local and
systemic circulation.
In isolated human arteries in vitro, Maguire et al. demonstrated that human urotensin II
receptors are present in vascular smooth muscle layers [Maguire et al 2000]. In
addition, they showed a positive response to urotensin II where the potency of urotensin
II in coronary, mammary and radial arteries was 50-fold greater than endothelin-1.
However, there were differences in the characteristics of the responses. The maximal
responses to endothelin-1 were consistently greater than those to urotensin II, and 30%
of the arteries failed to respond to urotensin II, whereas all responded to endothelin-1.
Recently, Hillier et al. examined a wide range of human arteries and veins of differing
calibre in vitro, and found no effect of human urotensin II [Hillier et al 2001], The
reason for this is not yet clear. Ames et al. performed a detailed in vivo study of the
systemic haemodynamic response to urotensin II in non-human primates [Ames et al
1999], At lower systemic doses of urotensin II, Ames observed positive inotropism,
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whereas at higher doses urotensin II induced ischaemic myocardial dysfunction and
extreme rises in peripheral resistance. On the basis of early human in vitro and the in
vivo cynomolgus monkey data, we hypothesised that urotensin II would cause
constriction of resistance vessels of the human forearm and raise blood pressure. Based
on a forearm blood flow of 50mL/min and an infusion rate of 300pmol/min, the
estimated local plasma concentration of urotensin II in the infused arm in our study
would be 6 nmol/L, similar to those causing vasoconstriction in human in vitro studies
[Maguire et al 2000]. Nevertheless, we found no effect of urotensin II at 300pmol/min
for 20 min in either the brachial artery or dorsal hand vein. This contrasts markedly with
the local vascular responses in humans to other paracrine and endocrine mediators, such
as endothelin-1 and ANGII, both ofwhich cause -40% reduction in forearm blood flow
at only 5pmol/min [Clark et al 1989; Haynes and Webb 1994], and suggests that
urotensin II does not play an important role in regulating peripheral vascular tone.
Indeed, during intra-arterial infusion of ANGII a 10 fold increases in plasma
concentrations ofANGII in the non-infused arm caused mean arterial pressure to rise by
- 15mmHg [Labinjoh et al 2000], whereas 30 fold increases in plasma urotensin II had
no effect.
In any negative study it is important to consider the possibility that a real effect on
arteriolar tone was missed. This is particularly important given the variability in the
responses of isolated human vessels to urotensin II [Maguire et al 2000; Stirrat et al
2001; Douglas et al 2000; Hillier et al 2001]. This is unlikely to be the case because
there was no suggestion of groups of responders and non-responders from the 15
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subjects who received urotensin II over a wide range of doses. In addition, brachial
infusion studies are an extremely powerful tool for detecting vasoactive responses,
usually requiring no more than 6 subjects to have a high degree of confidence in
showing statistically significant effects [Benjamin et al 1995],
Previously, Gibson found that fish urotensin II caused endothelium dependent
vasodilatation at low dose, prior to vasoconstriction, in rat aortic tissue [Gibson 1987],
This raised the possibility that human urotensin II may induce activation of nitric oxide
synthase and subsequent release of nitric oxide. To date, only one in vitro study has
studied the influence ofnitric oxide synthase on responses to urotensin II [MacLean et al
2001], using L-N-nitro-arginine methylester (L-NAME) to inhibit nitric oxide synthase
in isolated pulmonary vessels [MacLean et al 2001], L-NAME increased maximal
responses but not potency of urotensin II in rat main pulmonary artery. L-NAME also
enhanced maximal responses to urotensin II in human pulmonary arteries, though only 3
of 10 vessels responded to urotensin II, and then only with very variable contractions. In
the current studies, nitric oxide and prostanoid production were inhibited, using standard
techniques. Even so, we were unable to unmask vasoconstriction to urotensin II in
either human resistance or capacitance vessels in vivo.
The lack of response of resistance vessels in vivo may be due to low receptor density or
poor coupling to signal transduction mechanisms at this site, perhaps as part of inter¬
species variation. The proximal aorta seems to be most sensitive to urotensin II and it is
possible that subtle effects on large arteries are caused by urotensin II but not detected
using routine haemodynamic assessment. The in vivo effects of urotensin II on human
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large arteries merits further investigation. A possible alternative explanation for the lack
of effects of urotensin II is high receptor occupancy. Studies with urotensin II
antagonists in vivo can address this issue, and should allow the physiological role of
urotensin II in man to be more clearly defined. In conclusion, we have found no
evidence of local or systemic haemodynamic effects of urotensin II in vivo despite
infusion ofurotensin II at doses that increase plasma concentrations 30-fold.
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CHAPTER 5
STUDIES OF HAEMODYNAMIC PARAMETERS DURING SYSTEMIC
INTRAVENOUS INFUSION OF UROTENSIN II
JT Affolter, IB Wilkinson, MJ Winter, RJ Balment, DE Newby and DJ Webb. No
effect on central or peripheral blood pressure of systemic urotensin II infusion in man.
British Journal ofClinical Pharmacology 2002;54:617-621.
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5.1 SUMMARY
In rodent and primate studies, urotensin II is an extremely potent vasoconstrictor peptide
with effects in the central aortic and arterial vasculature as well as on cardiac function.
The aim of the present study was to assess systemic haemodynamic responses to
intravenous urotensin II infusion in man. In 10 healthymale volunteers, intravenous
urotensin II (3, 30 and 300 pmol/min) and saline placebo were given on separate
occasions in a single-blind randomised manner. Systemic haemodynamics and arterial
stiffness were assessed by sphygmomanometry, transthoracic bioimpedance, and pulse
wave analysis. Plasma urotensin II immuno-reactivity was measured by radio¬
immunoassay. Intravenous urotensin II infusions were well tolerated with no adverse
clinical effects and no electrocardiographic changes. Circulating plasma urotensin II
immuno-reactivity increased from baseline of 16 ± 1 to 1460 ± 82 pmol/mL during
infusion of urotensin II at 300 pmol/min (P<0.001). However, there were no significant
placebo adjusted changes in heart rate (95% confidence intervals: -3.6 to +4.4 /min),
mean arterial pressure (-5.8 to +1.7 mmHg) or cardiac index (-0.1 to +0.4 L/min/m2).
There were no changes in augmentation index (-4.1 to +5.2 %) or pulse wave velocity (-
1.3 to +0.3 m/s). In conclusion intravenous urotensin II infusion did not affect systemic
haemodynamics or arterial stiffness, despite achieving a ~ 100-fold increase in plasma
immuno-reactivity. We conclude that urotensin II is unlikely to have a physiological
role in the short term regulation of vascular tone or blood pressure in man. Further
confirmatory studies with urotensin II receptor antagonists are required.
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5.2 INTRODUCTION
Urotensin II is a vasoactive peptide found in the circulation ofman and many animal
species [Affolter and Webb 2001; Coulouarn et al 1998; Ames et al 1999; Nothacker et
al 1999], In man it has 11 amino acids differentiating it from other species with 12 and
13 amino acids such as the fish and frog [Affolter and Webb 2001]. Urotensin II is the
most potent arterial vasoconstrictor yet discovered, having sustained effects in in vitro
studies in animals [Douglas et al 2000], In addition, it has profound and potentially
lethal pressor and vasoconstrictor effects in non-human primates in vivo [Ames et al
1999],
Human urotensin II was first isolated in man from subgroups ofmotor neurones in the
spinal cord [Coulouarn et al 1998], Outwith the central nervous system, the kidney has
the highest expression of human prepro-urotensin II mRNA and this, therefore, appears
to be the most likely source of circulating urotensin II in man [Nothacker et al 1999].
The distribution ofurotensin II receptors has been mapped using immuno-
histochemistry, confirming target binding sites in cardiovascular tissues; including
coronary arteries, internal mammary arteries and ventricular cardiomyocytes [Ames et al
1999; Maguire et al 2000], Thus, it can be considered likely that urotensin II functions
as an endocrine hormone with cardiovascular actions [Affolter and Webb].
Both the anatomical location and species appear to dictate the observed vascular
response to UII administration [Douglas et al 2000]. In the rat, there is a marked
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vasoconstrictor response in the proximal aorta with continuous reduction in activity
progressively down the arterial tree [Itoh et al 1987], Previous human in vivo studies,
carried out in our laboratory, show that high concentrations of urotensin II delivered by
the intra-brachial route have no effect on local vascular tone in the forearm [Wilkinson
et al 2002]. This is in contrast to a similar, but not placebo-controlled, study performed
recently by Bohm and Pernow [Bohm and Pemow 2002], However, these studies
primarily aimed to assess responses of the resistance arterioles and did not specifically
examine the integrated response of the arterial system. This omission may be important
because the extreme pressor and myocardial ischaemic responses seen in non-human
primates may have resulted from large artery stiffening or vasoconstriction [Ames et al
1999],
The arterial pressure waveform alters with progression down the arterial tree. This is
due to local variations in vascular stiffness as well as superimposition of the reflected
pressure waveform that returns to the central arteries and aorta in diastole [Nichols and
O'Rourke 1998]. Augmentation index is dependent on three components: pulse wave
velocity, site ofwave reflection in the vascular tree and amplitude of the reflected wave.
Increased stiffness of small arteries causes an increase in the amplitude of the reflected
wave and effectively moves the site ofwave reflection proximally. However, increasing
large artery stiffness is manifested as a rise in pulse wave velocity. Aortic pulse
pressure depends on aortic stiffness and the degree ofwave reflection. These stiffness-
related effects produce an increase in central aortic pressure and cardiac afterload, and a
reduction in coronary perfusion pressure due to the movement of the reflected wave into
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systole. By measuring augmentation index a composite measure of central arterial
stiffness can be obtained, whereas aortic pulse wave velocity examines the contribution
of large arterial stiffness [Nichols and O'Rourke 1998; Wilkinson et al 2001; O'Rourke
et al 2001],
Given the data from studies in non-human primates, we hypothesised that systemic
administration of urotensin II would act physiologically as a circulating hormone to
increase large arterial stiffness and blood pressure. Our aim was, therefore, to
investigate the effects of intravenous urotensin II infusion on a range of systemic





Ten healthy men, mean age 42 ±4 years (range 22 to 55), were recruited into the study,
which was conducted with the approval of the local research ethics committee (Lothian
Research Ethics Committee) and the written informed consent of each subject. Subjects
abstained from caffeine containing drinks, alcohol and tobacco over the preceding 24
hours and were fasted from midnight prior to the study.
5.3.2 Drugs
Human UII (Peptide Institute, Osaka, Japan) was dissolved in saline (0.9% Baxter
Healthcare Ltd., Norfolk, UK) and administered intravenously at 1 mL/min via a
constant rate infusion pump (IVAC). Purity and fidelity of human urotensin II from the
Peptide Institute was established by high performance liquid chromatography and
microsequencing. Biological activity and potency of the human urotensin II peptide was
confirmed in the rat proximal aorta (data not shown). Doses used in study protocols
were based on our initial studies giving urotensin II via the intra-brachial route
[Wilkinson et al 2002],
5.3.3 Study design
Augmentation index was determined from the radial artery using the technique of pulse
wave analysis (SphygmoCor 2000 version 6.2; PWV Medical PTY Ltd, Sydney,
Australia) as previously described [Nichols and O'Rourke 1998], Pulse wave velocity
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was determined using pulse wave analysis (SphygmoCor 2000 version 6.2) combined
with electrocardiographic monitoring at the carotid artery (adjacent to the thyroid
cartilage) and femoral artery (immediately below the inguinal ligament). The separation
of the pulse waveforms was defined as the difference between the distances from the
sternal notch to the inguinal ligament and to the thyroid cartilage. All measurements
were made in duplicate and mean values used in subsequent data analysis. Recordings
with systolic and diastolic variability in excess of 5% were excluded and the
measurement repeated. Blood pressure was recorded in the non-infused arm using a
validated oscillometric sphygmomanometer (HEM 705CP, Omron, Japan) [O'Brien et al
1996]. Cardiac index was assessed using a validated transthoracic electrical
bioimpedance technique [Northridge et al 1990] (NCCOM3, BoMed Irvine CA, USA).
Mean arterial pressure was defined as the diastolic pressure plus a third of the pulse
pressure. Systemic vascular resistance index was defined as the mean arterial pressure
divided by the cardiac index and then converted from Wood units to dynes.s.m2/cm5 on
the basis that 1 Wood unit approximates to 80 dynes.s.m2/cm5. Throughout the study
continuous electrocardiographic monitoring was employed and a 12 lead
electrocardiogram (ECG) recorded at baseline, during the last 2 minutes of the 300
pmol/min infusion of urotensin II and at the end of the final saline infusion.
5.3.4 Systemic intravenous infusion protocol
Each subject attended on two occasions at least one week apart and received an initial 30
min saline infusion during which baseline recordings were performed at 15, 22 and 25
min. Baseline bloods and ECG were obtained at 28 min, just prior to urotensin II or
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placebo infusion. This was followed by a single blind randomised administration of
either urotensin II (3, 30 and 300 pmol/min for 20 min at each dose) or saline for one
hour, before a final 30 min saline infusion. Blood pressure, heart rate, cardiac index and
augmentation index were recorded at 5 and 12 min, pulse wave velocity at 15 min, and
blood samples obtained and a 12 lead electrocardiogram taken at 18 min of each
infusion period.
5.3.5 Plasma urotensin II concentrations
Venous blood (10 mL) was drawn during the last 2 min of each infusion period from a
cannula sited in the non-infused arm. Samples were collected into ethylene diamine
tetra-acetic acid, immediately centrifuged at 3,000 g for 10 min at 4°C and the plasma
stored at -80°C until subsequent analysis. Plasma levels of urotensin II immuno-
reactivity were determined using an acetic acid extraction technique and radio¬
immunoassay, with rabbit anti-flounder urotensin II, as described previously [Wilkinson
et al 2002; Winter et al 1999] and are expressed in the results as pmol/mL.
5.3.6 Statistical analysis
All results are expressed as mean ± SEM. The AIx and PWV values represent change
from baseline. Data were analysed using ANOVA with repeated measures. Statistical
significance was taken at the 5% level. Previous studies carried out in our department
using noradrenaline infusions had 98% power to detect a change of 7% in 8 volunteers at
a significance level of 0.05 [Wilkinson et al 2001],
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5.4 RESULTS
Baseline heart rate, cardiac index, blood pressure, augmentation index, pulse wave
velocity and plasma urotensin II concentrations were similar on the two study days. The
baseline augmentation index and pulse wave analysis raw data recordings were 13 ± 4%
and 5.9 ± 0.3 m/sec respectively. Both values were consistent with other healthy
subjects from our local population with similar demographics. All subjects were
symptom-free throughout the studies: specifically, there were no reports of chest pain,
headache or abdominal pain. There were also no changes in continuous single lead
cardiac monitoring and 12 lead electrocardiograms throughout the studies. There were
no significant changes in systemic haemodynamic parameters or central aortic stiffness
during either saline placebo or urotensin II infusion (Figure 5.1). At the highest infusion
rate of 300 pmol/min, plasma urotensin II immuno-reactivity increased 91-fold (16 ± 1
to 1460 ± 82 pmol/mL) in the systemic venous plasma (n=10; P<0.001). Despite this,
there were no significant placebo adjusted changes in heart rate (0.4, -3.6 to +4.4 /min:
mean difference, 95% confidence interval), mean arterial pressure (-2.0, -5.8 to +1.7
mmHg), cardiac index (0.2, -0.1 to +0.4 L/min/m2) and systemic vascular resistance
index (-160, -396 to +76 dynes.s.m2/cm5). Moreover, arterial stiffness was unaffected,
with no demonstrable alterations in augmentation index (+0.5, -4.1 to +5.2 %) or pulse
wave velocity (-0.5, -1.3 to +0.3 m/s).
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Figure 5.1.
Mean pulse wave data, haemodynamic parameters (displayed as lines) and plasma
urotensin II concentration (UII; displayed as histogram; pmol/mL) during intravenous
urotensin II infusion. Mean augmentation index (AIx; ■; %), pulse wave velocity
t—i 9
(PWV; □; m/sec), cardiac index (CI; O; L/min/m ), systemic vascular resistance index



















































This is the first in vivo study ofwhich we are aware in which systemic intravenous
administration ofurotensin II has been used to increase circulating peptide
concentrations in man. There were no demonstrable effects of urotensin II on systemic
haemodynamics or arterial stiffness, although plasma urotensin II immuno-reactivity
increased by nearly 100-fold. This contrasts with the modest 2-fold elevation of plasma
urotensin II in renal disease [Totsune et al 2001].
Our findings contrast with in vivo studies in non-human primates, where urotensin II
caused potent pressor and vasoconstrictor effects [Ames et al 1999]. Moreover, the in
vivo human studies done by B5hm and Pernow and ourselves, an intra-arterial urotensin
II infusion of 300 pmol/min did not alter systemic blood pressure [Wilkinson et al 2002;
Nichols and O'Rourke 1998], an intra-arterial infusion rate that we demonstrated to raise
systemic plasma urotensin II immuno-reactivity by 30-fold [Wilkinson et al 2002],
Such an increase is not always sufficient to cause peripheral haemodynamic effects, as
can be seen with vasopressin, which requires a 10 to 100-fold rise in plasma
concentrations [Landry and Oliver 2001; Aylward et al 1986], In vitro studies have
shown that the rat aorta is highly responsive to urotensin II, particularly in its proximal
region [Douglas et al 2000; Maguire et al 2000]. However, against the reproducible in
vitro pharmacological response to urotensin II in cardiovascular tissues from animals,
findings reported in human in vitro studies are inconsistent [Affolter and Webb 2001;
Hillier et al 2001], Our results may reflect a fundamental difference in species response,
103
although the in vitro human aortic response is currently unknown. As it appears likely
that urotensin II is an endocrine hormone with receptors located in human
cardiovascular tissues, the question remains as to its function in human vascular
physiology.
We have previously demonstrated dose-dependent increases in augmentation index with
intravenous infusion of pressor hormones, including angiotensin II and norepinephrine
[Wilkinson et al 2001]. Moreover, intravenously infused peptides, such as angiotensin
II and endothelin-1, cause a significant rise in mean arterial blood pressure for only a 2
and 3-fold rise in plasma concentrations respectively [Motwani and Stuthers 1992;
Kaasjager et al 1995]. In the present study, we administered 300 pmol/min (total dose
of 85 pmol/kg) ofurotensin II for 20 minutes and achieved a 91-fold increase in plasma
urotensin II immuno-reactivity. This was associated with no symptoms, no
electrocardiographic changes, and no alterations in systemic haemodynamic parameters.
When given intravenously, urotensin II caused profound ischaemic electrocardiographic
changes in non-human primates in association with cardiac dysfunction and even death
[Ames et al 1999]. Ames et al used doses of urotensin II up to 3000 pmol/kg and
reported that doses <30 pmol/kg increased cardiac output, while doses >30 pmol/kg
increased vascular resistance and decreased myocardial function [Ames et al 1999],
However, due to safety concerns, we did not use either bolus injections or the higher
doses of urotensin II that were used in the non-human primate in vivo studies. It may be
the case that urotensin II has a role in cardiovascular regulation in man that is not
addressed directly in our studies. For instance, it has recently been suggested that
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urotensin II may influence atherogenesis by augmenting the mitogenic activity of sub-
fractions of oxidised low density lipoprotein [Watanabe et al 2001] and even that
urotensin II might have a role in the regulation of insulin release [Silvestre et al 2001].
In conclusion, we have observed no change in arterial stiffness or systemic
haemodynamic parameters, including blood pressure in response to intravenous
urotensin II infusion in vivo in man despite a nearly 100-fold increase in plasma
urotensin II immuno-reactivity. These findings indicate that urotensin II is unlikely to
have a major physiological role in the regulation of vascular tone and blood pressure in
man. Further confirmatory studies using urotensin II receptor antagonists will be
required before firm conclusions can be drawn about the possible role of urotensin II in
human vascular physiology and disease.
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CHAPTER 6
INTRA ARTERIAL VASOPRESSIN IN THE HUMAN FOREARM:
PHARMACODYNAMICS, REPRODUCIBILITY AND THE ROLE OF NITRIC
OXIDE
JT Affolter, SP McKee, AH Salem, R Jones, DE Newby, DJ Webb. Intra-arterial
vasopressin in the human forearm: pharmacodynamics, reproducibility and the role of
nitric oxide. Clinical Pharmacology and Therapeutics 2003;74:9-16.
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6.1 SUMMARY
Diverse vascular effects have been ascribed to vasopressin, including the potential to
cause vasodilatation, vasoconstriction and nitric oxide release. The study aims were to
establish the pharmacodynamics, reproducibility and nitric oxide dependence of its
vasomotor actions in the forearm resistance vessels. Blood flow was measured in both
forearms of 12 healthy men using venous occlusion plethysmography. Continuous and
discontinous doses of intra-brachial vasopressin (1-300 pmol/min) were administered.
To assess the contribution ofnitric oxide, vasopressin was co-administered with the
'nitric oxide clamp', a balanced co-infusion of L-NG-monomethylarginine (a nitric oxide
synthase inhibitor) and sodium nitroprusside (an exogenous nitric oxide donor) to block
endogenous nitric oxide production and restore normal basal blood flow respectively.
Vasopressin produced dose-dependent and biphasic change in blood flow with a
maximum reduction of 22±5% at 3 pmol/min (PO.Ol) and increase of 80±30% at 300
pmol/min (P<0.01). There were no significant differences in repeated responses
obtained either within or between days. Repeated discontinuous dosing did not change
the magnitude of the maximum vasoconstriction or vasodilatation, but prolonged
continuous infusions produced maximal vasodilatation at 12 min that subsequently
underwent substantial tachyphylaxis (P=0.04). Although there was no augmentation of
vasoconstriction, the 'nitric oxide clamp' abolished vasopressin induced vasodilatation
(P<0.05). Intra-arterial vasopressin causes a reproducible dose-dependent biphasic
change in forearm blood flow. Vasomotor responses are time-dependent with a modest
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delay to peak vasodilatation and tachyphylaxis with prolonged sustained infusions.
Nitric oxide release provides a major contribution to vasopressin induced vasodilatation
but does not directly oppose low dose vasopressin induced vasoconstriction.
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6.2 INTRODUCTION
Arginine vasopressin is an endocrine hormone that originates from the posterior pituitary
and is primarily secreted in response to osmotic stimuli and hypotension. Outwith the
central nervous system, it has physiological effects on arteries and renal collecting ducts
to produce vasomotor and anti-diuretic effects respectively [Landry and Oliver 2001],
These actions play a role in the pathophysiology of conditions, such as heart failure and
cirrhosis, where high plasma vasopressin concentrations are associated with fluid
retention. The development of selective and non-selective vasopressin receptor
antagonists may provide a novel therapeutic approach in the treatment of these
conditions [Burrell et al. 2000]. The physiological study of such antagonists, in local
vascular models in man, necessitates insight into vasopressin responses in the chosen
study model. To date, studies using the robust methodology of forearm
plethysmography and intra-arterial drug infusion, have focused only on dose response
relationships and not addressed issues such as onset and offset of effects, the potential
for tachyphylaxis or, reproducibility.
The actions of vasopressin are mediated through 3 G-protein coupled receptors: the VI,
V2 and V3 receptors. Only the VI and V2 receptors appear to be present in vascular
tissue and these are linked to differing second messenger systems, namely phospholipase
C and adenylate cyclase respectively. The V1 receptor is present on vascular smooth
muscle and mediates arterial vasoconstriction [Hirsch et al. 1989, Imaizumi et al. 1992],
Although the physical presence of extra-renal V2 receptors in vascular smooth muscle or
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endothelium has yet to be demonstrated by either radio-ligand binding ormRNA
expression [Philips et al 1990], there is strong pharmacological evidence for their
existence. Intra-arterial infusion of desmopressin, a synthetic V2 receptor agonist, and
high dose vasopressin both cause vasodilatation in the human forearm [Hirsch et al
1989] that can be abolished by selective V2 antagonism [Tagawa et al. 1995]. In
addition, patients with congenital diabetes insipidus due to a genetic defect in the V2
receptor do not vasodilate with intra-arterial desmopressin and demonstrate only
vasoconstriction with vasopressin [Van Lieburg et al. 1995], In vivo evidence, using
superseded methods, suggested that vasopressin-induced vasodilatation is mediated by
the release ofnitric oxide [Tagawa et al. 1993; Van Lieburg et al. 1995], Furthermore,
it has been proposed that V2 receptor mediated vasodilatation to vasopressin has a
greater dependence on nitric oxide release than that associated with desmopressin [Van
Lieburg et al. 1995],
Vasopressin causes profound vasoconstriction ofhuman mesenteric arteries in vitro
[Ohlstein et al. 1986]. However, intravenous vasopressin infusion causes only modest
systemic hemodynamic effects in healthy volunteers [Aylward et al. 1986].
Examination of the direct vascular responses to vasopressin using intra-arterial infusion
and venous occlusion plethysmography has demonstrated variable responses, finding
both vasoconstriction and vasodilatation [Susuki et al. 1989] or vasodilatation alone
[Hirsch et al. 1989]. Moreover, intra-brachial vasopressin can simultaneously cause an
increase in total limb blood flow but skin pallor by means of a reduction in forearm skin
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blood flow [Hayoz et al. 1997]. Thus, the vasomotor actions of vasopressin appear to
vary with both dose and vascular bed affected.
The aim of the present study was to describe the forearm vascular actions of vasopressin
in vivo in man to facilitate studies with vasopressin antagonists. We wished to establish
the pharmacodynamics and reproducibility of responses to intra-brachial vasopressin,




These studies were conducted with the approval of the local research ethics committee
and the written informed consent of each subject. The investigations conformed to the
principles of the Declaration of Helsinki. Twelve healthy men, mean age 42 ± 4 years
(range 23-64), were recruited. Subjects were fasted from midnight before each study
(water consumption was not restricted) and abstained from caffeine containing drinks,
alcohol and smoking for the preceding 24 hours.
6.3.2 Drugs
Arginine vasopressin (Pitressin™, Goldshield, U.K.), sodium nitroprusside (SNP; David
Bull Laboratories, Warwick, UK) and L-7V°-monomethylarginine (L-NMMA; Clinalfa,
Laufelfingen, Switzerland) were aseptically prepared and dissolved in saline (0.9%
Baxter Healthcare Ltd., Norfolk, UK).
6.3.3 Study design
To ensure a stable baseline and maintain cannula patency, saline was infused for 30 min
before drug infusion protocols were commenced. The total rate of infusion was kept
constant at 1 mL/min throughout all studies. Forearm blood flow was measured
simultaneously in both arms by venous occlusion plethysmography [Whitney 1953;
Benjamin et al. 1995], as previously described [Wilkinson and Webb 2001]. Forearm
blood flow was measured over the last 3 min of every 6 min period. In protocols 1 and
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3, dose infusion was continued for 4 furthermin to allow blood pressure and pulse
recordings using a validated oscillometric sphygmomanometer (HEM 705CP, Omron
Japan) [O'Brien et al. 1996]. The last five plethysmography recordings of forearm
blood flow were averaged to determine flow in each arm. Blood pressure and heart rate
were recorded over the brachial artery in the non-infused arm. Mean arterial pressure
was defined as diastolic pressure plus 1/3 of the pulse pressure.
6.3.4 Protocol 1. Dose-response of vasopressin
On two occasions, at least one week apart, each of 8 subjects received a 30 min saline
infusion followed by either vasopressin or saline placebo in a randomised cross-over
manner. Vasopressin was infused at 1, 3, 10, 30, 100, 300 pmol/min for 10 min at each
dose.
6.3.5 Protocol 2. On and offset of vasopressin action
Based on the results ofprotocol 1, eight subjects attended on two occasions separated by
at least a week and received a 24 min infusion of saline followed by either 3 or 300
pmol/min of vasopressin. Subjects received 3 separate infusions of intra-arterial
vasopressin for 6, 12 and 18 min, each separated by 24 min of saline infusion. Forearm
blood flow recordings were made every 6 min throughout the study. The same subjects
re-attended a further occasion and received 48 min of 300 pmol/min intra-arterial
vasopressin followed by 48 min of saline.
113
6.3.6 Protocol 3. Reproducibility
To determine within-day and between-day reproducibility of the vasopressin responses,
eight subjects attended on two occasions. Subjects received a 30 min infusion of saline
followed by vasopressin at 3, 30 and 300 pmol/min followed by saline for 30 min before
receiving repeated infusion of vasopressin at the same doses.
6.3.7 Protocol 4. Vasopressin and the 'nitric oxide clamp'
Six subjects, who originally took part in protocol 1 participated in a 'nitric oxide clamp'
[Verhaar et al. 1998]. After 30 min saline infusion L-NMMA was infused intra-
arterially at 4 pmol/min to block endogenous nitric oxide generation [Vallance et al.
1989] and forearm blood flow was restored to within 10% of baseline by a titrated co-
infusion of sodium nitroprusside, an endothelium independent nitric oxide donor (mean
dose 0.5 nmol/min, range 0.3-0.8). On restoration of forearm blood flow vasopressin
was co-infused at 3, 30 and 300 pmol/min, each for 18 min.
6.3.8 Statistical analysis
All results are expressed as mean ± SEM. Data for forearm blood flow have been
expressed as a percentage change from baseline forearm blood flow ratio (the quotient of
infused arm and non-infused arm blood flow) [Benjamin 1995]. To assess the offset of
vasopressin response in protocol 2, the rate of decline in blood flow response per minute
was calculated for each response. In protocol 3, within-day and between-day
reproducibility was assessed using the method of Bland and Altman [Bland and Altman,
1986] and coefficients of repeatability were determined for 95% confidence intervals
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using the Student's t distribution. The Bland and Altman method considers the
reproducibility between repeated measurements of the same subjects, using the same
method on different occasions. The coefficient of reproducibility is then calculated as
1.96 times the standard deviation of the differences between the two measurements.
Data were analysed using ANOVA and Student's paired ?-test as appropriate. Statistical
significance was taken at P<0.05.
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6.4 RESULTS
Subjects were Caucasian and had a mean age of 42 ± 4 years (range 23-64), mean body
mass index of 24 ± 0.5 kg/m2 (range 21-26) and a mean arterial pressure 85 ± 3 mmHg
(range 74-100). All subjects were symptom free and the studies were well tolerated with
no significant side effects. Throughout all studies there were no significant changes in
non-infused forearm blood flow, mean arterial pressure or heart rate (ANOVA P=0.1,
P=0.9, P=0.5 respectively).
6.4.1 Protocol 1. Dose-response of vasopressin
Baseline non-infused and infused forearm blood flows were 3.8 ± 0.7 and 3.7 ± 0.7
mL/100 mL tissue/min respectively. Although unchanged during placebo infusion,
forearm blood flow demonstrated a dose-dependent biphasic response to vasopressin
(Figure 6.1; ANOVA PO.OOl) with a 22.5 ± 4% and 22.5 ±11% reduction in blood
flow during 3 and 10 pmol/min respectively (/-tests, P=0.006 and 0.03 respectively) and
an 80 ± 30% increase during 300 pmol/min (/-test, /Ml.OOb). Maximal vasodilatation
responses were observed for all 8 subjects during 300 pmol/min, however, maximal
vasoconstriction was observed in 4 subjects at 10 pmol/min.
6.4.2 Protocol 2. Onset and offset of vasopressin action
Baseline non-infused and infused forearm blood flows were 2.7 ± 0.3 and 2.7 ± 0.4
mL/100 mL tissue/min respectively. Infusion of repeated doses of 3 pmol/min
vasopressin caused a reduction in forearm blood flow of 21 ±4, 12 ± 4 and 17 ± 5%
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(Figure 6.2: P=0.02, 0.01 and 0.003 respectively). Infusion of repeated doses of 300
pmol/min vasopressin increased forearm blood flow by 119 ± 32, 103 ± 21 and 119 ±
31% (Figure 6.2: P=0.01, <0.001 and 0.01 respectively). A consistent maximal increase
in forearm blood flow was achieved at 12 min after starting vasopressin infusion
regardless of dose duration. Continued infusion of vasopressin from 6 to 12 and 18 min
significantly slowed the offset of vasodilatation from 10 ± 1.5 to 7 ± 0.7 and 5 ±
0.3%/min respectively (ANOVA, P=0.001). Although there is a suggestion of a similar
trend for the vasoconstrictor effect this did not reach statistical significance (ANOVA,
P=0.2).
During prolonged infusion of 300 pmol/min vasopressin, % change in forearm blood
flow ratio increased to a maximum of 126 ± 42% after 12 min (Figure 6.3: ANOVA,
P<0.001) and fell to 39 ± 15% by 48 min (Mest, P=0.04). After cessation of vasopressin
infusion, % change in forearm blood flow ratio remained consistently below baseline
flow (Mest, P=0.03).
6.4.3 Protocol 3. Reproducibility
Baseline non-infused and infused forearm blood flows were 3.4 ± 0.6 and 3.6 ± 0.7
mL/100 mL tissue/min respectively. There was good reproducibility of the vasopressin
vasomotor responses with no significant differences in within- or between-day responses
(Table 6.1).
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6.4.4 Protocol 4. Vasopressin and the 'nitric oxide clamp'
Baseline non-infused and infused forearm blood flows were both 2.5 ± 0.2 mL/100 mL
tissue/min. Infusion of L-NMMA reduced forearm blood flow ratio by 30 ± 3% (Figure
6.4: ANOVA, P=0.002) and co-infusion of sodium nitroprusside (mean dose 0.5
nmol/min, range 0.3 to 0.8) restored baseline blood flow (2.5 ± 0.2 compared to 2.5 ±
0.2 ml/100ml tissue/min, P=0.9). Subsequent co-infusion of 3 and 30 pmol/min
vasopressin reduced forearm blood flow ratio by 19 ± 5 and 22 ± 4% fP=0.03 and
P=0.002 respectively), although blood flow returned to baseline during 300 pmol/min
vasopressin (P=0.5).
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Percentage change in forearm blood flow during vasopressin 1, 3, 10, 30, 100, 300
pmol/min (•) and saline placebo infusion (O). * P<0.05, ** P<0.01, Student's t-test












Percentage change in forearm blood flow during infusion of vasopressin for 6, 12 and 18
min of either 3 (•) or 300 (O) pmol/min. * P<0.05, ** P<0.01, Student's /-test


























Percentage change in forearm blood flow during infusion of 48 min of 300 pmol/min
AVP infusion. * ,P<0.05, ** P<0.01, Student's /-test compared to saline baseline.








Percentage change in forearm blood flow during 3, 30 and 300 pmol/min vasopressin in
the presence of the 'nitric oxide clamp'. ** P<0.01 compared to saline baseline,




























We have shown that intra-brachial vasopressin infusions are well tolerated, reproducible
and cause a dose-dependent biphasic blood flow response with modest vasoconstriction
at lower doses (3-30 pmol/min) and substantial vasodilatation at higher doses (>100
pmol/min). The vasomotor response is time-dependent with a modest delay to peak
vasodilatation and tachyphylaxis with prolonged sustained infusions. Nitric oxide
release provides a major contribution to vasopressin induced vasodilatation but does not
directly oppose low dose vasopressin induced vasoconstriction.
Our findings are consistent with previous clinical studies using comparable doses of
vasopressin [Suzuki et al. 1989, Tagawa et al 1993, Tagawa et al 1995] that have
demonstrated a similar magnitude of vasopressin induced vasoconstriction (28%
reduction in flow) and vasodilatation (126% increase in flow). It is likely that
vasoconstriction is mediated by a direct action on vascular smooth muscle VI receptors
[Imaizumi et al 1992] and that vasodilatation is mediated through vascular V2 receptors.
However, receptor affinities for vasopressin do not readily explain the dose-dependent
biphasic response since, in comparison to the VI receptor, vasopressin has near double
the affinity for the V2 receptor [Thibonnier et al 1998]. In addition, very small changes
in plasma vasopressin concentrations have renal V2 receptor mediated anti-diuretic
effects and, in contrast to renal responses, vasodilatation was only observed with very
high and supra-physiological local vasopressin concentrations. This suggests that there
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is a higher threshold for pharmacodynamic responses mediated by the vascular V2
receptor and its second messenger system compared to the renal V2 receptors.
We have demonstrated that maximal vasoconstrictor and vasodilator responses were
unchanged with repeated vasopressin infusions. However, peak vasodilatation was
achieved at 12 min regardless of the duration of the infusion, even when less than 12
min, and prolonged infusion beyond 12 min was associated with tachyphylaxis to
vasopressin. The length of infusion determined the offset of action with a slower fall in
response seen with longer infusion times. This profile of the vasomotor responses may
relate to the physiology of the vasopressin receptor. When bound by vasopressin, the
majority of the VI and V2 receptor are internalised by the cell and only recycled to the
cell surface once the agonist is displaced [Thibonnier et al. 2001]. It is likely that the
peak response requires the majority of receptors to be present on the cell surface and that
waning of the response occurs because of receptor-ligand internalisation. However,
during intermittent infusion of vasopressin, the receptors may have time to recycle back
to the cell surface ensuring an undiminished maximal response. The delayed peak
vasodilatation seen with the brief 6 min vasopressin infusion also suggests some
damping or delay in the second messenger pathway that is not seen with other G-protein
coupled receptor responses, such as those to bradykinin and substance P. The more
protracted offset of the vasodilatation with longer vasopressin infusions may also
represent rebinding of receptors that have been recycled back to the cell surface
membrane.
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Previous in vitro [Katusic et al. 1984 and 1992] and in vivo studies [Tagawa et al. 1993,
Rector et al. 1996] have suggested that nitric oxide contributes to the vasodilatation
produced by vasopressin. In the first in vivo study intra-arterial L-N -
monomethylarginine (L-NMMA), a nitric oxide synthase inhibitor, was co-infused with
vasopressin and appeared to inhibit the vasodilatation. However, L-NMMA inhibits
basal nitric oxide production and thereby causes vasoconstriction and a reduction in
basal forearm blood flow. Such basal changes in vessel geometry and blood flow may,
therefore, make the interpretation of subsequent responses difficult [Webb 1995;
Benjamin et al 1995]. Co-infusion of sodium nitroprusside, an exogenous nitric oxide
donor, with L-NMMA can be used to restore the baseline blood flow and vessel
geometry by replacing endogenous with exogenous nitric oxide; the so-called 'nitric
oxide clamp' [Stroes et al 1997]. This technique establishes a stable baseline forearm
blood flow that can be maintained for up to 120 min and permits the assessment of
vascular responses in the absence of endogenous nitric oxide synthesis [Verhaar et al
1998]. Using the 'nitric oxide clamp' we have shown abolition of vasopressin-induced
vasodilatation, consistent with V2 receptor activation causing endothelial nitric oxide
generation. Without further study, it is unclear if the restoration of baseline blood flow
with high dose vasopressin is attributable to tachyphylaxis of the vasoconstriction or
whether there is some residual nitric oxide independent vasodilatation. Although
vasopressin causes vasoconstriction at lower doses, there remains the possibility that
even greater vasoconstriction could have been achieved in the absence of the potentially
counteracting V2 receptor effects. However, against this, we were unable to
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demonstrate potentiation of the vasoconstrictor response during the 'nitric oxide clamp',
suggesting that the vascular V2 receptor is unstimulated at these concentrations.
In conclusion, we have found that intra-arterial vasopressin is well tolerated and causes a
reproducible dose-dependent and biphasic blood flow response. The assessment of
forearm vasomotor responses to vasopressin provides a practical, reliable and sensitive
method of assessing the in vivo efficacy of selective and non-selective VI and V2
receptor antagonists in man.
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CHAPTER 7
THE STUDY OF VASOPRESSIN AND A SELECTIVE VI RECEPTOR
ANTAGONIST IN THE HUMAN SKIN MICROCIRCULATION
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7.1 SUMMARY
Arginine vasopressin is both an anti-diuretic and vasoactive peptide which causes
vasoconstriction via the VI receptor and, in some vascular beds, vasodilatation via V2
like vascular receptors. Using laser Doppler flowmetry, we hypothesised that in the skin
microcirculation vasopressin would cause vasoconstriction and that a novel selective
peptide VI receptor antagonist (d(CH2)s[Tyr(Me)2,Dab5]AVP ) would attenuate this
response. We aimed to study the effects of a dose range of vasopressin and the control
vasoconstrictor, endothelin-1 (ET-1), on skin blood flow before combination with the
VI antagonist.
Skin blood flow was measured in 15 healthy men using laser Doppler flowmetry
coupled with intra-dermal injection of drugs. Comparative dose ranges 3xl0"14 to
3xl0~u mol/10 pL ofboth vasopressin and endothelin-1 were administered, followed by
an extended dose range of vasopressin 10~17 to 10"11 mol/10 pL to obtain an EC50. A
dose range of lxlO"20 to lxlO"10 mol/10 pL d(CH2)5[Tyr(Me)2,Dab5]AVP was injected
prior to combination with lxlO"15, lxlO"14, lxlO"13 mol/10 pL vasopressin with either
saline placebo or lxlO"12 mol/10 pL d(CH2)5[Tyr(Me)2,Dab5]AVP.
Vasopressin and endothelin-1 caused a dose dependent reduction in skin blood flow
(ANOVA P<0.001). The EC50 for vasopressin was 7 ± 1.3x10"15 mol/10 pL. The VI
antagonist, d(CH2)5[Tyr(Me)2,Dab5]AVP alone, did not change skin blood flow
(ANOVA P=0.3) nor did it alter vasoconstrictor effects of co-administered vasopressin
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(ANOVA P=0.3). Antagonist activity was confirmed in rat biopressor assays and aphi
value of 8.07 obtained. We conclude that d(CH2)5[Tyr(Me)2,Dab5]AVP is not a potent
VI antagonist in vivo in the skin microcirculation in man. The failure of the VI
antagonist to alter the vasoconstrictor responses to vasopressin may reflect a low
potency and /or inter-species variation.
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7.2 INTRODUCTION
Arginine vasopressin, an endocrine hormone released from the neurohypophysis, is
responsible for the regulation ofplasma osmolarity, body water and support ofblood
pressure in response to hypotension and increased plasma osmolarity. Vasopressin has
been implicated in disease states such as congestive cardiac failure [Goldsmith et al
1983; Szatalowicz et al 1981] and end stage cirrhosis [Burmeister et al 1983; Akriviadis
et al 1997] where the vasopressin axis is stimulated and plasma concentrations are high,
especially when hyponatraemia is a feature [Szatalowicz et al 1981]. Vasopressin
antagonists may have a potential therapeutic role in such patient groups.
Extensive studies in healthy human volunteers have been performed to assess the
physiology of vasopressin. Intra-arterial infusion in man results in a bi-phasic forearm
blood flow responses [Affolter et al 2003] where low dose (3 pmol/min) cause
vasoconstriction via VI receptors [Hirsch et al 1989; Imaizumi et al 1992], and at higher
doses (300 pmol/min) a nitric oxide [Affolter et al 2003] and V2 receptor mediated
vasodilatation [Tagawa et al 1995], However, not all vascular beds show the same
pattern of responses and although the composite measure of forearm blood flow
increases over the higher dose range of intra-arterial vasopressin, there are
vasoconstrictor effects on both the radial artery and skin blood flow for all infusion
rates.
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From non-peptide antagonist studies, it appears likely there are only VI receptor
mediated effects on skin blood flow [Weber et al 1997], although these studies involved
systemic dosing with an orally active VI antagonist. Of the peptide VI receptor
antagonists, there have been numerous problems with poor selectivity and co-
antagonism of oxytocin receptors, however d(CH2)5[Tyr(Me)2,Dab5]AVP, the
diaminobutyric acid analogue of d(CH2)5Tyr(Me)AVP, is highly selective for VI
receptors [Chan et al 1996],
The assessment of skin blood flow can be made non-invasively using laser Doppler
flowmetry [Holloway and Watkins 1977; Schabauer and Rooke 1994], This is a
reproducible method [Kubli et al 2000] dependent on the principle of a Doppler shift in
frequency of the reflected He-Ne laser light from flowing red blood cells in the skin
microcirculation. Combined with intra-dermal drug injection this method has been
successfully used to study vasoactive peptides including endothelin-1 and its antagonists
[Wenzel et al 1993].
We hypothesised that vasopressin would induce vasoconstriction in skin
microcirculation. We also hypothesised that the selective VI antagonist
d(CH2)5[Tyr(Me)2,Dab5]AVP, would not change basal skin blood flow but would




Studies were conducted with the approval of the local research ethics committee and the
written informed consent of each subject. The investigations conformed to the
principles of the Declaration ofHelsinki. Fifteen healthy men, mean age 26 ± 2 years
(range 21 to 46) were recruited. Subjects were asked to fast from midnight before each
study (water consumption was not restricted) and to abstain from caffeine containing
drinks, alcohol and smoking over the preceding 24 hours.
7.3.2 Drugs
Arginine vasopressin (Pitressin™, Goldshield, UK), endothelin-1 (Clinalfa,
Laufelfingen, Switzerland) and d(CH2)5[Tyr(Me)2,Dab5]AVP (Clinalfa, Laufelfmgen,
Switzerland) were aseptically prepared and dissolved in saline (0.9% Baxter Healthcare
Ltd.,Norfolk, UK). The antagonist activity of d(CH2)5[Tyr(Me)2,Dab5]AVP was
confirmed using an in vivo biopressor assays with pentobarbitone anaesthetised rats.
7.3.3 Study design
Studies were performed with subjects resting supine in a quiet clinical laboratory which
was maintained at a constant temperature of 22-24°C. After 20 min rest, 4 injection sites
were selected on the volar aspect of each forearm. After baseline recordings sites were
injected with 10 pL drug and/or 10 pL saline placebo using a disposable 29.5 SWG 0.5
mL graduated syringe (Becton-Dickinson, Dublin, Ireland). Injections were made
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strictly intra-dermally, producing a visible symmetrical wheal, if this was not the case,
the injection site was excluded. Recordings were made for 30 seconds at each site
immediately after injection, 5 min, 10 min and every 10 min thereafter for 1 hour. The
location of both dose and control sites were randomised using a Latin square design in
all studies.
7.3.4 Protocol 1. Dose response to vasopressin and endothelin-1
On two occasions, at least 1 week apart each of 8 subjects received either vasopressin or
endothelin-1 in the concentration range of 3xl0"14, lxlO"13, 3xlO"13, lxlCT12, 3xlCT12,
lxlO"11, 3xl0~n mol/10 pL.
7.3.5 Protocol 2. Extended dose range for vasopressin
On one occasion, each of 8 subjects received vasopressin in the concentration range of
lxlO"11, lxlO"13, lxlO"14, lxlCT15, lxlO"16, lxlO"17 mol/10 pL.
7.3.6 Protocol 3. Dose range of d(CH2)s[Tyr(Me)2,Dab5]AVP
On one visit 8 subjects received d(CH2)5[Tyr(Me)2,Dab5]AVP in the concentration range
lxlO"10, lxlO"12, lxlO"14, lxlO"16, lxlO"18, lxl0~20mol/10 pL.
7.3.7 Protocol 4. Co-administration of vasopressin and
d(CH2)5 [Tyr(Me)2,Dab5]AVP
On one visit 8 subjects received lxlO"15, lxlO"14, lxlO"'3 mol/10 pL vasopressin co-
injected with 10 pL saline placebo and the same doses of vasopressin co-injected with
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lxl 0"12 mol/10 pL d(CH2)5[Tyr(Me)2,Dab5]AVP. Controls of saline alone and saline
and d(CH2)5[Tyr(Me)2,Dab5]AVP were used.
7.3.8 Rat biopressor assay
Six adult male Wistar rats (Charles River, Margate, England), mean body weight 327 g,
range 245-401 g, were anaesthetised with 60 mg/kg intra-peritoneal pentobarbital and
continuous 6 mg/h intra-venous pentobarbitol for steady levels of anaesthesia. Body
temperature was maintained at 36 to 37 °C with a heating blanket and a tracheal cannula
was inserted with tidal volume and respiratory rate monitored by an electrospirometer
(MacLab). The right carotid and femoral arteries were cannulated for blood pressure
monitoring and drug administration respectively. Arginine vasopressin (Pitressin™,
Goldshield, UK) and d(CH2)5[Tyr(Me)2,Dab5]AVP (Clinalfa, Laufelfingen, Switzerland)
were prepared in and dissolved in saline (0.9% Baxter Healthcare Ltd., Norfolk, UK)
and drugs were administered in 0.1 mL volumes then washed in with 0.2 mL saline.
Doses of 10, 30, 100, 300, 1000 ng vasopressin and 5, 10, 20, 40 ng
d(CH2)5[Tyr(Me)2,Dab5]AVP were used. After stable anaesthesia was achieved
sequential vasopressin doses 10, 30, 100 ng, were administered followed by a 20 minute
washout phase and reappraisal of level of anaesthesia prior to antagonist dosing. Five
minutes after the antagonist was given a further sequential 30, 100, 300 ng vasopressin
was given followed by another 20 minute washout phase. Again, levels of anaesthesia
were assessed for stability and a second antagonist dose given before 100, 300, 1000 ng
of vasopressin. In the first 3 rats 5 and 10 ng d(CH2)5[Tyr(Me)2,Dab5]AVP were given
before the two sequential vasopressin dose ranges and in the final 3 rats 20 and 40 ng
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doses were used. Recording of the mean arterial blood pressure was made in the 15
seconds before drug injection and at the point ofmaximal change during the 120
seconds immediately following drug injection. The effects of drugs were determined by
comparing responses to agonist alone and following administration of antagonist. Data
are expressed change in mean arterial blood pressure ± SEM and as EC50 values ± SEM.
The pA2 value (the log antagonist dose required to necessitate a doubling of the agonist
dose to achieve the same pharmacodynamic response) was obtained from the x axis
intercept of a Schild plot of log antagonist dose vs. log (dose response-1). The animal
studies were performed in accord with European Community guidelines, approved by
the institutional ethics committee and licensed under the UK Home office regulations.
Studies were done with this investigator present, but not performed by himself due to
licensing restrictions on those allowed to perform animal studies.
7.3.8 Statistical analysis
All results are expressed as mean ± SEM. As previously described intra-dermal
injection of saline alone causes an increase in skin blood flow [Holloway 1980] that
diminished over time. The area under the curve for both saline control and drug
injection sites were calculated and used to determine differences between them and
expressed in arbitrary perfusion units (PU). The EC50 was defined as the concentration
of agonist that provoked a response halfway between the baseline and maximum
response. It was calculated using data from the extended dose range of vasopressin,
with Graph Pad Prism™. Statistical analysis was performed using repeated measure
ANOVA and for individual comparisons data were analysed using Student's Ctest.
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Statistical significance was taken at PO.05.
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7.4 RESULTS
All subjects were symptom free throughout the studies and the intra-dermal injections of
all drugs were well tolerated. There was no significant difference in response to saline
controls throughout all studies (ANOVA P=0.3).
7.4.1 Protocol 1. Dose response to vasopressin and endothelin-1
Vasopressin caused a reduction in skin blood flow (Figure 7.1; ANOVA PO.OOl) for all
doses tested. A reduction in skin blood flow was observed for all doses of endothelin-1
(Figure 7.1; ANOVA PO.OOl).
7.4.2 Protocol 2. Extended dose range for vasopressin
Vasopressin caused an incremental reduction in skin blood flow (Figure 7.2; ANOVA
PO.OOl) with significant differences between the lowest dose (lxlCT17 mol/10 pL) and
highest dose (lxlO"11 mol/10 pL; t-test, PO.OOl). The EC50 value was calculated to be
7 ± 1.3xlCT15 mol/10 pL.
7.4.3 Protocols 3 and 4. Dose range of d(CH2)5[Tyr(Me)2,Dab5]AVP and co¬
administration of vasopressin and d(CH2)s[Tyr(Me)2,Dab5]AVP
Intra-dermal injection of d(CH2)5[Tyr(Me)2,Dab5]AVP caused no significant change in
skin blood flow (Figure 7.3; ANOVA P=0.3). The co-administration of antagonist with
vasopressin did not alter the response to vasopressin (Figure 7.4; ANOVA P=0.3).
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7.4.4 Rat biopressor assay
Vasopressin caused a dose dependent rise in mean arterial blood pressure. Injection of
10 and 100 ng vasopressin increased blood pressure by 3 ± 1 and 16 ± 2 mmHg
respectively (P<0.001). Pre-treatment with 40 ng d(CH2)5[Tyr(Me)2,Dab5]AVP reduced
the expected rise in mean arterial pressure during 100 ng vasopressin dosing to 6 ± 3
mmHg (P=0.05, n=3). The EC50 of vasopressin was 93 ± 20 ng and with 40 ng
d(CH2)5[Tyr(Me)2,Dab5]AVP pre-treatment, the EC50 rose to 500 ± 157 ng (P=0.05,
n=3). ThepA2 was calculated to be 8.07.
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Figure 7.1
Skin blood flow responses to a dose range to vasopressin and endothelin-1. * PO.05,
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Figure 7.2
Skin blood flow responses to an extended dose range of vasopressin showing EC50 of
7xl0~15 mol/10 pL. Saline placebo (O) and vasopressin (#). * P<0.05, ** P<0.01,
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Figure 7.3





12Skin blood flow responses to vasopressin with saline placebo (O) and with 1x10"
mol/10 pL vasopressin antagonist (•). ANOVA P=0.3.
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7.5 DISCUSSION
We have confirmed the potential for both vasopressin and endothelin-1 to cause
vasoconstriction in the skin microcirculation of healthy male volunteers and that the
EC50 for vasopressin is 7xl0"1:> mo1/10 pL. The VI receptor antagonist
d(CH2)5[Tyr(Me)2,Dab5]AVP did not alter vasoconstriction associated with vasopressin
in man but was found to be a potent inhibitor of the vasopressin pressor effects in rats
We conclude that d(CH2)5[Tyr(Me)2,Dab5]AVP is not a potent VI antagonist in vivo in
the skin microcirculation in man
Both vasopressin and its analogues, such as ornipressin, have been used in similar
studies and cause potent vasoconstriction [Fruhstorfer and Heisler 1994; Weber et al
1997] in the skin microcirculation. Flowever, we have observed consistent
vasoconstriction occurring at doses up to 100-fold lower than previously described
[Weber et al 1997], During the study of endothelin-1, we observed a dose dependent
reduction in skin blood flow for all doses, including those 30-fold less than used in
previous studies [Brain et al 1989], The disparity from previous results may reflect the
different equipment used to measure skin blood flow. In our study the Moor Instruments
Laser Blood Flow Monitor MBF3D uses near infra-red light as opposed to the red light
used by Weber et al and Brain et al, which in Caucasian skin can potentially have half
the depth of light penetration [Vongsavan and Matthews 1993], Drug injection
techniques were similar although the injection volumes were 50pL and the drug vehicle
differed. We calculated an EC50 value based on the amount of vasopressin required to
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vasopressin required to generate a 50 % change from baseline when the maximal
response had been determined. Other studies do not cite an EC50 value for their intra¬
dermal vasopressin studies so we are unable to directly compare our results with those of
others.
Vasopressin release as a response to shock increases circulating vasopressin
concentration by up to 28-fold greater than the non-stimulated plasma concentration
[Landry and Oliver 2000]. This increase is far greater than that required for anti-diuretic
effects at the renal V2 receptors. We hypothesised that the VI receptor antagonist
would not alter basal skin blood flow on the basis that in healthy volunteers, vasopressin
would be most unlikely to contribute to basal vascular tone compared to other vasoactive
peptides such as endothelin-1 [Haynes and Webb 1994], As the VI antagonist did not
alter the effect of exogenous vasopressin on skin blood flow we cannot confirm this
hypothesis using this antagonist.
Co-administration of vasopressin doses around the EC50 concentration with the VI
receptor antagonist d(CH2)5[Tyr(Me)2,Dab5]AVP unfortunately did not show the
predicted antagonism. Inter-species difference may account for the lack of effect and
this is the first time d(CH2)5[Tyr(Me)2,Dab5]AVP has been used in vivo in human
subjects. Our wish was to use the most selective peptide VI antagonist. However,
during the construction of this antagonist, the amino acid asparagine at position 5 is
replaced by diaminobutyric acid, that whilst greatly increases the selectivity for VI
receptors, has a detrimental effect on potency [Chan et al 1996], This could account for
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the lack of antagonist effect. To confirm antagonist activity we performed a rat
biopressor assay using pentobarbitone anaesthetised Wistar rats and were able to
confirm antagonist activity with apA.2 value of 8.07. The biopressor assay is however
limited in terms of the number of animals used. There are at however 20 amino acids
that differ within the extra-cellular loops of the rat and human VI receptors [Thibonnier
et al 2001], These residues have been shown to be critical to the inter-species variation
in the binding of other VI receptor antagonists such as the non-peptide VI receptor
antagonist OPC-21268 [Thibonnier et al 2000].
Potential limitations in our study include the co-administration ofboth drug and
antagonist in a single preparation. An approach of 2 injections, with the antagonist first
could have been performed but the skin trauma of 2 injections at one site may simply
increase the error ofmeasurement. Furthermore, this antagonist had never been used in
human in vitro or in vivo studies before and antagonist doses had to be estimated from
animal models.
We have shown vasopressin to be a potent vasoconstrictor in the human skin
microcirculation. The lack of effect of the antagonist, d(CH2)5[Tyr(Me)2,Dab5]AVP,
may have been due to either insufficient potency or inter-species variation.
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CHAPTER 8
THE STUDY OF VASOPRESSIN PEPTIDIC VI AND V2 RECEPTOR
ANTAGONISTS IN THE HUMAN FOREARM CIRCULATION
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8.1 SUMMARY
In man arginine vasopressin causes vasoconstriction via the VI vascular receptor and
vasodilatation in some vascular beds via V2 vascular receptors. Vasopressin peptide
antagonists have been used with variable success due to selectivity problems. Using the
reproducible and sensitive method ofbilateral venous occlusion plethysmography
coupled with intra-arterial drug infusion, we hypothesised that the VI receptor
antagonist, d(CH2)5[Tyr(Me)2,Dab5]AVP, would reduce vasopressin induced
vasoconstriction and enhance its induction of vasodilatation. Conversely, the V2
antagonist, d(CH2)5[D-Ile2-Ile4-Ala9]AVP, would attenuate vasopressin induced
vasodilatation.
Forearm blood flow was measured in 6 healthy male subjects using bilateral venous
occlusion plethysmography during intra-arterial infusion of 1, 3, 10, 30, 100, 300, 1000
and 3000 pmol/min ofVI antagonist, V2 antagonist or saline placebo given in a
randomised double blind manner. A further study combined sequential vasopressin dose
ranges of 3, 30 and 300 pmol/min with VI antagonist, V2 antagonist or saline placebo in
a randomised double blind manner. Heart rate and blood pressure were recorded
through out each study. The study was well tolerated and no significant changes in heart
rate, blood pressure or flow in the non-infused arm were observed. Compared to
placebo infusion, both VI and V2 antagonists did not change forearm blood flow
(ANOVA, P=0.6 and P=0.9 respectively). Infusion of vasopressin caused a dose
dependent biphasic change in blood flow (ANOVA, P0.001), with vasoconstriction
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with 3 pmol/min (PO.Ol) and vasodilatation with 300 pmol/min. Compared to saline
placebo, neither the V1 nor V2 antagonist, co-infused at 20 nmol/min, altered the dose
dependent biphasic response pattern to vasopressin (ANOVA, P=0.1 for both).
We conclude that neither the VI nor V2 antagonist affected forearm blood flow, nor did
they alter the normal vascular effects of vasopressin. This indicates that
d(CH2)5[Tyr(Me)2,Dab5]AVP and d(CH2)5[D-Ile2-Ile4-Ala9]AVP do not appear to be
efficacious in blocking VI or V2 receptors in man in vivo. This may reflect inter¬
species differences in antagonist activity or low potency of the antagonists.
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8.2 INTRODUCTION
As an endocrine hormone vasopressin is responsible for osmoregulation and
maintenance ofblood pressure by means ofperipheral arterial vasoconstriction in
response to hypotension. An activated vasopressin axis has been implicated in the
pathophysiology ofheart failure, a condition characterised by increased vascular tone
and fluid retention and vasopressin receptor antagonists have subsequently become a
focus for therapeutic intervention [Burrell et al 2000].
The use of peptidic vasopressin antagonists had a chequered history. Although non-
peptide antagonists have been helpful in forwarding pharmacological knowledge,
peptide antagonists have suffered from poor selectivity and inter-species variation.
From human intra-arterial studies, vasopressin shows a dose dependent biphasic
response in forearm blood flow [Suzuki et al 1989; Tagawa et al 1993, Affolter et al
2003], although others have shown only vasoconstriction [Weber et al 1997] or
vasodilatation [Hirsch et al 1989].
From studies using vasopressin antagonists, it is likely that V1 receptors [Hirsch et al
1989; Imaizumi et al 1992] mediate vasoconstriction and V2 receptors [Tagawa et al
1995] mediate nitric oxide dependent vasodilatation [Chapter 6]. However, few studies
have directly assessed the effects ofVI antagonists and have instead employed systemic
oral or intra-venous antagonist administration prior to a dose range of intra-arterial
vasopressin [Hirsch et al 1989; Imaizumi et al 1992],
155
7
Of the peptide antagonists d(CH2j5[Tyr(Me)"]AVP has high antagonist activity against
the VI receptor [Kruszynski et al 1980] but it also has equivalent anti-oxyntic effects
and mild V2 anti-diuretic agonist effects [Manning and Sawyer 1986] making it less
than ideal in terms of selectivity. Although not traditionally associated with
cardiovascular regulation, oxytocin receptors are involved with plasma volume
regulation and have been located in the rat vena cava and aorta [Jankowski et al 2000],
The more recent d(CH2)5[Tyr(Me)2, Dab^]AVP has no V2 agonist nor oxytocin receptor
antagonist effects [Chan et al 1996] making it relatively unique amongst peptide
antagonists. Slightly less success has been seen in the development of V2 peptide
antagonists with persistent problems in selectivity, although the production of
d(CH2)5[D-Ile"-Ile4-Ala9]AVP [Sawyer et al 1987] saw superior selectivity being 83-
fold more selective for V2 than VI receptors. Vasopressin has yet to be studied against
the above antagonists in direct vascular studies in man.
We aimed to study the forearm blood flow responses to an intra-arterial dose range of
VI and V2 receptor antagonists before co-infusing vasopressin with each antagonist and
a saline placebo. We hypothesised that firstly, intra-arterial infusion of the VI
(d(CH2)5[Tyr(Me)2, Dab5]AVP) and V2 (d(CH2)5[D-Ile2-Ile4-Ala9]AVP) antagonists
alone would not alter forearm vascular tone. Secondly, vasopressin co-infusion with the
VI antagonist would reduce the vasoconstrictor effects of vasopressin and enhance





These studies were conducted with the approval of the local research ethics committee
and the written informed consent of each subject. The investigations conformed to the
principles of the Declaration ofHelsinki. Six healthymen, mean age 35 ± 5 years
(range 23-48), were recruited. Subjects were asked to fast from midnight before each
study (water consumption was not restricted) and to abstain from caffeine containing
drinks, alcohol and smoking over the preceding 24 hours.
8.3.2 Drugs
Arginine vasopressin (Pitressin™, Goldshield, U.K.), VI antagonist (d(CH2)5[Tyr(Me)2,
Dab5]AVP; Clinalfa, Laufelfmgen, Switzerland) and V2 antagonist (d(CH2)5[D-Ile2-Ile4-
Ala9]AVP; Clinalfa, Laufelfmgen, Switzerland) were aseptically prepared and dissolved
in saline (0.9% Baxter Healthcare Ltd., Norfolk, UK).
8.3.3 Study design
Studies were performed with subjects resting supine, in a quiet clinical laboratory that
was maintained at a constant temperature of 22-24°C. The brachial artery of the non-
dominant arm was cannulated with a 27 SWG gauge steel needle (Cooper's Needle
Works, U.K.) under local anaesthesia, (1% lignocaine; Astra Pharmaceuticals Ltd.,
Hertfordshire, UK). This was connected to a constant rate infusion pump (IVAC) via a
16-gauge epidural catheter (Portex Ltd. UK). Saline was infused for 30 min before drug
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infusion protocols were commenced to ensure a stable baseline and maintain cannula
patency. The total rate of infusion was kept constant at 1 mL/min throughout all studies.
Forearm blood flow was measured simultaneously in both arms by venous occlusion
plethysmography [Benjamin et al. 1995], as previously described [Wilkinson and Webb
2001]. Forearm blood flow was measured over the later 3 min of a 6 min period, the
dose infusion was continued for 4 further min to allow blood pressure and pulse
recordings using a validated oscillometric sphygmomanometer (F1EM 705CP, Omron
Japan) [O'Brien et al. 1996]. The last five plethysmography recordings of forearm
blood flow were averaged to determine flow in each arm. Blood pressure and heart rate
were recorded in the non-infused arm. Mean arterial pressure was defined as diastolic
pressure plus 1/3 of the pulse pressure.
8.3.4 Protocol 1. Infusion of vasopressin peptide antagonists
On 3 occasions, at least 1 week apart, each of 6 subjects received in a randomised and
double blind manner, saline placebo, VI or V2 antagonist. Drugs were infused at 1, 3,
10, 30, 100, 300, 1000, 3000 pmol/min for 10 min at each dose.
8.3.5 Protocol 2. Co-infusion of vasopressin and saline placebo, VI and V2
antagonists
On 3 occasions, at least 1 week apart, the same 6 subjects received vasopressin at 3, 30
and 300 pmol/min for 10 min each, co-infused with saline. This was followed by saline
alone for 30 min before receiving a repeated infusion of vasopressin at the same doses
with a co-infusion of either saline placebo or 20 nmol/min ofVI or V2 antagonist given
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in a randomised and double blind manner. During co-infusions drug and placebo was
infused at 0.5 mL/min each.
8.3.6 Statistical analysis
All results are expressed as mean ± SEM. Data for forearm blood flow have been
expressed as a percentage change from baseline forearm blood flow ratio in the results
and figures (the quotient of infused arm and non-infused arm forearm blood flow) [Chin-
Dusting et al 1999, Wilkinson and Webb 2001]. Repeated measures ANOVA was used
to identify differences in forearm blood flow response. For single comparisons, data
were analysed using Student's paired t-test. Statistical significance was taken at P<0.05.
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8.4 RESULTS
All subjects were symptom free and the studies were well tolerated. There were no
significant differences in the basal forearm blood flow between infused and non-infused
arms and throughout all studies there were no significant changes in non-infused
forearm blood flow and mean arterial pressure or heart rate (ANOVA P=0.6, P=0.9 and
P=0.5 respectively).
8.4.1 Protocol 1. Infusion of vasopressin peptide antagonists
Baseline forearm blood flow for non-infused and infused arms were 4.7 ±1.0 and 4.8 ±
1.0 mL/1 OOmL tissue/min respectively. Forearm blood flow was unchanged during
infusion ofVI and V2 antagonist compared to placebo (Figure 8.1; ANOVA P=0.6 and
P=0.9 respectively).
8.4.2 Protocol 2. Co-infusion of vasopressin and saline placebo, VI and V2
antagonists
Baseline values for non-infused and infused arms were 3.0 ± 0.6 and 3.4 ± 0.6
mL/1 OOmL tissue/min respectively. During both first and second vasopressin dose
ranges co-infused with saline and then saline placebo, vasopressin caused a bi¬
directional response (Figure 8.2, ANOVA P0.001 for both) with an 18 ± 2% and 18 ±
7% reduction in blood flow respectively during infusion of 3 pmol/min vasopressin (t-
tests, P=0.002 and 7^=0.06) and blood flow increases of 95 ± 17% and 52 ± 17%
respectively during infusion of 300 pmol/min of vasopressin of (/-tests, P=0.02 and
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P=0.05). Compared to the co-infusion of saline with the second dose range of
vasopressin, co-infusion of 20 nmol/min of either VI or V2 antagonist did not change
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Figure 8.1
Percentage change in forearm blood flow during saline placebo (O), VI antagonist (A),
V2 antagonist (■) 1, 3, 10, 30, 100, 300, 1000, 3000 pmol/min.
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Figure 8.2
Percentage change in forearm blood flow during sequential infusions of vasopressin 3,
30, 300 pmol/min. First dose range — O- -with saline and second dose range with
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We have shown that infusions of d(CH2)5[Tyr(Me)2,Dab5]AVP and d(CH2)5[D-Ile2-Ile4-
Ala9]AVP peptidic antagonists are well tolerated but did not change forearm blood flow
when infused alone or in combination with vasopressin.
We had hypothesised that V1 receptor antagonism would reduce vasoconstriction and
enhance vasodilatation induced by co-infused vasopressin whereas V2 receptor
antagonism would attenuate the vasopressin induced vasodilatation during co¬
administration of exogenous vasopressin. Previous human studies using oral systemic
non-peptide VI antagonists such as OPC-21268, decreased the vasoconstrictor response
to intra-arterial vasopressin and augmented its vasodilator effects [Imaizumi et al 1992],
Unlike the composite forearm blood flow measurement, when specifically observed,
radial artery flow is reduced, regardless of the infused intra-arterial dose [Hayoz et al
1996; Weber et al 1997]. This response has also been antagonised by intra-arterial SR.
49059, a later and more specific non-peptide antagonist [Weber et al 1997]. Peptide
antagonists such as d(CH2)5[Tyr(Me)2]AVP have not been studied directly by intra-
arterial infusion against vasopressin, although d(CH2)5[Tyr(Me) ]AVP has been given as
a systemic intra-venous dose prior to intra-arterial vasopressin but showed only an
enhancement of forearm vasodilatation [Hirsch et al 1989]. The peptidic antagonist,
des-Gly(CH2)5D-Tyr(Et)Val-AVP, has been used in human in vitro studies and shown to
antagonise desmopressin (a human V2 agonist) induced endothelial dependent
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vasodilatation in human veins [Aldasoro et al 1997]. However, this particular antagonist
also has partial VI antagonist effects.
Despite our studies it remains unclear whether vasopressin contributes to resting
vascular tone in healthy subjects given that we were unable to demonstrate effective
blockade of the VI and V2 receptors in man in vivo when antagonists were infused alone
or co-infused with exogenous vasopressin. It is biologically plausible that vasopressin
would not contribute to basal vascular tone as vasopressin induced vasoconstriction is
usually part of either a non-sustained physiological response to shock or related to a
chronic pathological state, such as heart failure, that is characterised by an abnormally
high vascular tone. Moreover, limited systemic studies with the less selective VI
peptide antagonist d(CH2)s[Tyr(Me)2]AVP, failed to induce haemodynamic effects in
man [Gavras et al 1984; Hirsch et al 1989],
In making our choice of antagonist, we aimed to use the most selective available
vasopressin receptor antagonist, although neither of the antagonists had been used in
human clinical studies, and like many before, had only been tested in rats. Using the
higher antagonist infusion rate of 20 nmol/min and assuming forearm blood flow to be
20 to 50 mL /min (taking account of vasopressin induced vasodilatation during the dose
range), we would have achieved a local tissue concentration of 4 nmol/mL of
d(CH2)s[Tyr(Me)2, Dab3]AVP (at highest forearm blood flow) in the studied vascular
bed, thus markedly exceeding the plasma concentration of 0.1 nmol/mL of
d(CH2)5[Tyr(Me)~]AVP required to antagonise the effects of vasopressin infused by
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systemic intra-venous infusion [Gavras et al 1984], The production of
d(CH2)s[Tyr(Me)2, Dab^AVP involved the substitution ofAsn at position 5 with
diaminobutyric acid which increases greatly the selectivity but not potency [Chan et al
1996], which could be a reason for the lack of an effect. To confirm antagonist activity,
we carried out rat biopressor assays using pentobarbitone anaesthetised Wistar rats and
were able to confirm antagonist activity and apk.i value of 8. However, there are at
least 20 amino acids that differ within the extra-cellular loops of the rat and human V1
receptors [Thibonnier et al 2001]. These residues have been shown to be critical to the
inter-species variation in the binding of the non-peptide V1 receptor antagonist OPC-
21268 [Thibonnier et al 2000].
The original development of the V2 antagonist d(CH2)5[D-Ile2-Ile4-Ala9]AVP was
directed against renal V2 receptors [Saywer et al, 1988] and it is unknown how closely
they resemble the vascular V2 like receptors, as no V2 receptors have been directly
isolated from human vascular smooth muscle and endothelium to make the comparison.
In conclusion we have detected no change in forearm blood flow during VI and V2
antagonist infusion alone nor change in the vascular activity of vasopressin. There are a
number of possible reasons for the lack of activity including low potency, inter-species




CONCLUSIONS AND FUTURE DIRECTIONS
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9.1 UROTENSIN II
Overall, it has become clear that urotensin II causes diverse vascular effects in
mammals, based not only on species [Douglas et al 2000], but also on the vascular
region tested [Gibson 1987; Itoh et al 1987]. However, during our studies ofurotensin
II, we were unable to demonstrate changes in either vascular tone or systemic
haemodynamics as assessed by local and systemic vascular studies.
Our findings were in contrast to the forearm studies carried out by Bohm and Pernow
[Bohm and Pernow et al 2002]. When using a similar dose range they demonstrated a
31% reduction in forearm blood flow. There were a number ofmethodological
differences, principally, in their case, not taking into account possible changes in the
non-infused arm and not using the forearm blood flow ratio as the overall measurement,
the optimal measure of assessing vasoconstriction. In scrutinising our own studies to
ascertain why our results were different, we were able to confirm drug delivery to the
chosen vascular beds and verify both the pharmacological authenticity, by the drugs
amino acid sequence, and pharmacodynamic efficacy of our batch of urotensin II by
studying its effects on rat aorta in vitro. This was not done by Bohm and Pernow.
It has recently been postulated that such variability, or lack of observed response, could
be accounted for by the number of free receptors available for the ligand to exert its
action [Douglas 2003], The basis ofDouglas's postulate comes from observations
relating to pharmacokinetics of the ligand and receptor. Urotensin II binds with high
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affinity {Kd ~ 300 pM) to its receptor with a very slow dissociation time [Ames et al
1999; Maguire et al 2000]. Thus if the majority of receptors are occupied and perhaps
even activated, then no effect may be seen during the addition of exogenous urotensin II.
Plasma urotensin II concentrations are in the nanomolar range [Affolter et al 2002;
Dschietzig et al 2002; Heller et al 2002] which is well above the Ki of urotensin II for its
receptor. Furthermore, radioligand studies have shown only sparse binding in human
coronary and rodent aortic membranes [Maguire et al 2000; Itoh et al 1988], It may
well be the case that subtle changes in the numbers, and/or location of receptors
expressed, is the primary method of controlling urotensin II vascular effects. Moreover,
this mode of control would be less quickly exerted than a rapid rise in circulating
hormone in the presence of numerous unoccupied receptors, perhaps making urotensin II
a more chronic cardiovascular regulator than our short-term infusion studies have been
able to show. It is entirely possible that while the search for vascular effects of urotensin
II has not yielded significant results in humans it may have a completely different role in
physiology to the one hypothesised on this thesis. Urotensin II is known to have effects
in fish on membrane sodium transport, lipid and glucose metabolism [Bern et al 1985]
and Cortisol secretion [Kelsall and Balment 1998], These observations, taken together
with high expression of prepro-urotensin II in the human kidney [Nothacker et al 1999]
and the recognition of conservation of function under evolutionary pressures, would be
consistent with an endocrine role for urotensin II in sodium handling, and perhaps even
in the metabolic syndrome.
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9.2 UROTENSIN II: CLINICAL RELEVANCE AND FUTURE DIRECTIONS
Shortly after the completion of these healthy volunteer studies, a number of publications
reported the plasma concentrations of urotensin II in various disease states. Interestingly
several of the conditions seen to have elevated urotensin II concentrations are states
associated with fluid overload, namely, cardiac failure [Richards et al 2002; Douglas et
al 2002; Leong et al 2002; Dschietzig et al 2002], renal failure [Totsune et al 2001],
cirrhosis and portal hypertension, especially when associated with ascites [Heller et al
2002] and hypertension [Cheung et al 2004], Ong et al have recently reviewed other
situations associated with high plasma concentrations of urotensin II but not
characterised by overt fluid overload such as diabetes mellitus with or without
proteinuria , mitogenesis, ischaemic heart disease and pulmonary hypertension [Ong et
al 2005], Limited skin blood flow studies have been performed in subjects with
hypertension [Sondermeijer et al 2005], which is known to be associated with an
elevated urotensin II plasma concentration. A comparison was made between
hypertensive and normotensive volunteers with respective dose dependent
vasoconstrictor and vasodilatation responses observed. This was suggestive of urotensin
II having a contributory role in the increased vascular tone seen in those with
hypertension.
Although urotensin II has been found in high concentrations, the mode of this increase is
unknown. Whether this represents poor clearance or increased production is not clear.
The actual site of urotensin II release is likely to be the kidney but little is known about
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urotensin II metabolism and excretion. These points are highly relevant for the above
conditions, all of which have altered renal function. Some investigators have also
looked at the expression of urotensin II mRNA and receptor binding capacity and found
these to be increased in the myocardium of the failing human heart [Douglas et al 2002],
supporting the concept that urotensin II regulation may be at the receptor level.
The use of a highly selective human urotensin II receptor antagonist will no doubt help
clarify what role urotensin II plays in health and disease in man. Although not wholly
specific, a neuromedian B receptor antagonist, BIM-23127, has proven to be the most
potent urotensin II antagonist to date [Herold et al 2003]. If indeed receptor numbers
control the urotensin II response a well designed study will be required for any human in
vivo antagonist study. Future studies might include using firstly health volunteers with a
selective antagonist infused alone and then co-infusion with urotensin II in the forearm
vascular bed. Secondly, antagonist infusion in patient groups with elevated plasma
urotensin II concentrations may be revealing and helpful in delineating any
pathophysiological role of urotensin II. If such short term studies were to still reveal no
effects one may have to wait for an antagonist with a long half life so that temporal
differences in vascular responses to antagonist alone and to repeated local and systemic
infusion of urotensin II could be studied.
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9.3 VASOPRESSIN
In part, our aim in using vasopressin was to increase our knowledge of vasopressin
vascular responses before using vasopressin antagonists. There was also the opportunity
to assess vasopressin pharmacodynamics, such as, tachyphylaxis, its on and offset, and
the role of nitric oxide in vasopressin mediated vasodilatation. As a peptide to which
urotensin II could be compared, vasopressin is a vasoactive peptide with control over
renal tubular function and hence volume homeostasis, which itself has also been
implicated in fluid overloaded states such as heart failure [Goldsmith et al 1983;
Szatalowicz et al 1981] and end stage cirrhosis [Burmeister et al 1983; Akriviadis et al
1997],
We were able to reproduce the typical biphasic forearm vascular response to vasopressin
at equivalent doses to other studies where low intra-brachial infusion rates caused
vasoconstriction and higher rates caused a nitric oxide dependent vasodilatation
[Affolter et al 2003]. During the nitric oxide clamp, enhanced vasoconstriction response
to vasopressin was not observed, suggesting that the vascular V2 receptors are not
stimulated by low vasopressin concentrations. Tachyphylaxis seen during prolonged
infusion of vasopressin had not been demonstrated before. However, the oxytocin
receptor, which is very similar to the vasopressin receptors, has been shown to undergo
oxytocin induced desensitisation in cultured human myometrial myocytes, although this
did take up to 4 hours before 50% of peak effect was lost [Robinson et al 2003], It was
interesting to note the possible relationship between the on and offset of forearm blood
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flow responses and the known internalisation cycle of the vasopressin receptor/ligand
complex [Thibonnier et al 2001]. Return to the cell surface after agonist displacement
occurs, but at a reduced rate with waning of responses observed.
Although the peak effect is decreased and delayed, there are receptors capable of
binding vasopressin, unlike the postulated paucity of free urotensin II receptors. It is
also of note that circulating vasopressin concentrations are in the picomolar range
[Landry and Oliver 2001], an order ofmagnitude less than urotensin II. Few data exist
as regards the regulation of vasopressin receptor numbers in disease states, where high
plasma vasopressin concentrations have been found [Goldsmith et al 1983; Szatalowicz
et al 1981; Burmeister et al 1983; Akriviadis et al 1997].
The lack of effect of the peptidic antagonists has been a long term problem in
vasopressin research. Almost all VI peptide antagonists have some cross reactivity with
V2 receptors and the most selective ones tend to be less potent. The V2 antagonists are
even less selective, which creates problems in interpretation. We cannot conclusively
say that our dosing protocols or drug preparation was not to blame for the lack of
observed effect. Unfortunately the more selective and potent synthetic antagonists are
currently not available to us for clinical use.
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9.4 VASOPRESSIN: CLINCAL RELEVANCE AND FUTURE DIRECTIONS
Vasopressin antagonism has now become a therapeutic option for conditions such as
heart failure, incorporating long acting non-peptidic orally available agents such as
Tolvaptan, a selective V2 receptor antagonist which has led to a reduction in body
weight and normalisation of serum sodium in patients with hyponatraemia and cardiac
failure [Gheorghiade et al 2003]. The rationale for the use of a V2 antagonist is that a
reduction in the V2 receptor mediated reabsorption ofwater, i.e. the induction of an
aquaresis to accompany the loop diuretic driven natriuesis, would help ameliorate the
fluid overload state in cardiac failure. As yet no long term studies have taken place and
the most up to date results are tolerability studies. Vasopressin has also extended its role
in medicine as an inotrope in critical care where it has been studied with beneficial effect
in both haemorrhagic and septic shock [Dries 2003; Dunser et al 2002].
By gathering more information on the basic physiology of vasopressin, the methodology
of antagonist studies can be refined. Ofparticular interest will be the effects of
vasopressin and its antagonists on the endothelial cytokines such as 11-6, fibrinolytic and
haemostatic functions. Vasopressin is known to induce platelet aggregation [Thibonnier
et al 1999] and stimulation of the vascular V2 receptors causes release of t-PA, vWf,
factor VIII:C, IL-6 and TNF [Newby et al 2000; Kauffnann et al 2000], With the
introduction of vasopressin antagonists to the therapeutic regimens for common
cardiovascular conditions it will be important to know how the balance of these factors
will change.
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In looking to future studies, it seems reasonable to use forearm and skin blood flow
models. It would be helpful if the basic vasopressin responses could be assessed in
patients with cardiac failure where vasopressin plays a role in the pathophysiology.
Ideally safe, non-toxic, efficacious and more receptor-specific vasopressin antagonists
could be used to dissect physiology from pathophysiology, initially in healthy volunteers
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